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1. LIST OF ABBREVIATIONS 
 
293/uPAR = HEK293 cells overexpressing uPAR 
ATF = amino terminal fragment of uPA 
BSA = bovine serum albumin 
CFA = complete Freund’s Adjuvant  
CHO = chinese hamster ovary cells  
CNS = central nervous system 
CV = coefficient of variation 
D1 = domain 1 of uPAR 
D2 = domain 2 of uPAR 
D3 = domain 3 of uPAR 
DELFIA = dissociation-enhanced lanthanide fluorescence immunoassay 
DIC = Differential Interference Contrast microscopy 
ECM = extracellular matrix 
EGF = epidermal growth factor 
EGFR = epidermal growth factor receptor 
ER+ = estrogen receptor expressing cells 
ERK = extracellular signal-regulated kinase 
FAK = focal adhesion kinase  
FGF2 = fibroblast growth factor 2 
fMLP = formyl-Met-Leu-Phe peptide  
FN = fibronectin 
FPR = fMLP receptor  
FPRL-1 = fMLP receptor like-1 
 FPRL-2 = fMLP receptor like-2 
GFD = growth factor-like domain 
GPCR = G protein-coupled receptor 
GPI = glycophosphatidylinositol 
HEK293 = human embryonic kidney 293 cells 
HGF = hepatocytes growth factor 
HIF1α = hypoxia-inducible factor 1α  
HPLC = high-performance liquid chromatography 
IFA = Incomplete Freund’s Adjuvant 
IgG = immunoglobulin G 
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IP = intraperitoneal injection 
KD = kringle domain 
LDLR = low density lipoprotein receptor 
LPS = lipopolysaccharide 
LRP-1A = low density lipoprotein receptor-related protein-1A  
LRP-1B = low density lipoprotein receptor-related protein-1B 
LRP2 = low density lipoprotein receptor-related protein-2  
m/z = mass over charge ratio 
mAb = monoclonal antibody 
MALDI-TOF = Matrix-Assisted Laser Desorption/Ionization Time of Flight  
MAPK = mitogen-activated protein kinase  
MMP = matrix metalloproteinase 
MS = mass spectrometry  
MW = molecular weight  
NFκB = nuclear factor kappa B 
O/N = overnight 
PAI-1 = plasminogen activator inhibitor 1 
PAI-2 = plasminogen activator inhibitor 2 
PAN = Pan-apple domain  
PBS = phosphate buffered saline 
PBS-T = phosphate buffered saline containing 0.1% Tween-20  
PDGFRβ = platelet derived growth factor receptor β 
PFA = paraformaldehyde 
PLAU = uPA gene name 
PLAUR = uPAR gene name 
Plg = plasminogen 
Pli = plasmin 
PMSF = phenylmethanesulfonylfluoride 
PN-1 = protease nexin-1 
RCL = reactive centre loop 
RT = room temperature 
RTCA = Real-Time Cell-based Assay  
S/N = signal to noise ratio 
sc-uPA = single-chain uPA 
SD = standard deviation 
SDS-PAGE = Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis 
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SEM = standard error of the mean 
serpin = serine proteases inhibitor 
SMB = somatomedin B 
SPD = serine protease domain 
suPAR = soluble uPAR 
TAFI = thrombin-activatable fibrinolytic inhibitor 
tc-uPA = two-chain uPA 
TGFβ = transforming growth factor β 
TKR = tyrosine kinase receptor 
TNFα = tumour necrosis factor α 
tPA = tissue-type plasminogen activator 
TR-FIA = Time-Resolved Fluorescence Immunoassay  
uPA = urokinase-type plasminogen activator 
UTR = untraslated region 
VEGF = vascular endothelial growth factor  
VLDLR = very low density lipoprotein receptor 
VN = vitronectin 
w/w = weight/weight ratio 
α2M = α2-macroglobulin 
α2AP = α2-antiplasmin 
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3. ABSTRACT 	  
Urokinase (uPA) and its cell surface receptor (uPAR) have been implicated in a wide 
variety of biological processes related to tissue homeostasis. Moreover the uPA-system 
plays an important role in many pathological events, such as tumour cell migration and 
dissemination. On the one hand, the binding of uPA to uPAR favours extracellular 
proteolysis by enhancing cell surface plasminogen activation. On the other hand, it 
promotes cell adhesion and signalling through binding of the provisional matrix protein 
vitronectin (VN). Although the existence of feedback loops between the functions of uPAR 
in extracellular proteolysis, cell adhesion and signalling has been described, some aspects 
of this cross-talk are still poorly understood and not characterized experimentally. 
We here report that cell surface plasminogen activation induces a potent negative feedback 
on cell adhesion to VN. The feedback is predominantly caused by proteolytic cleavage of 
the RGD-motif in VN catalyzed by both uPA and plasmin. In this process the cell-adhesive 
properties of VN are impaired by disruption of the integrin binding site and release of the 
somatomedin B (SMB) domain responsible for binding of uPAR. Cleavage of VN by uPA 
displays a remarkable receptor-dependence and requires concomitant binding of both uPA 
and VN to uPAR suggesting that the hydrolysis is accelerated by a mechanism of substrate 
presentation. VN represents the first described uPAR-dependent substrate of uPA and our 
findings therefore identify a potential novel function of uPAR in focusing the proteolytic 
activity of the plasminogen activation system onto extracellular matrix-associated VN. 
Additionally, SMB-containing N-terminal VN fragments are released by several cancer 
cell lines in vitro and are detectable in human urines samples. We have thus developed a 
clinical grade immunoassay for the detection and quantification of such fragments in urine 
samples with the aim of using the levels of urinary VN fragments as a novel cancer 
biomarker. Our working hypothesis is that this biomarker may be used as an indirect 
functional measurement of the uPA-system activity in the tumour tissue. 
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Finally, we show that the specific urokinase inhibitor, plasminogen activator inhibitor 1 
(PAI-1), blocks the negative feedback mediated by uPA and behaves as a potent uPA-
dependent agonist of the interaction between uPAR and VN. Indeed, we report for the first 
time that the covalent complex between uPA and PAI-1 is endowed with higher agonistic 
activity compared to uPA. Taken together, these data might represent a molecular 
explanation of the poor clinical outcome observed in cancer patients with high levels of 





Proteases are present in all organisms from prokaryotes to eukaryotes. In the human 
genome there are more than 500 genes encoding for proteases1, which are involved in a 
variety of physiological processes. Their functions range from simple and non specific 
reactions, such those involved in food digestion, to highly orchestrated processes such as 
the blood clotting cascade, wound healing, immune and inflammatory cell migration and 
activation, apoptosis and angiogenesis. In addition, they have an important role in protein 
post-translational processing as well as in protein degradation.  
Proteases are classified in six classes: aspartic, glutamic, cysteine, serine, threonine and 
metallo proteases; depending on the mechanism of catalysis. In particular, serine proteases 
utilize a serine residue as the nucleophile to attack and hydrolyse the target peptide bond of 
the substrate. Indeed, the catalytic mechanism relies on the so-called catalytic triad, 
composed of three amino acids located in the active site of the enzyme: serine, histidine 
and aspartic acid. The histidine and the aspartic acid cooperate to polarize and activate the 
serine residue. 
Proteolytic reactions are highly regulated. In fact, most proteases are synthesised as 
inactive precursors, called zymogens, that are activated upon proteolytic cleavage, to 
ensure activation at the proper time in the correct localization. In addition, proteases often 
act within complex networks of inhibitors, receptors, substrates and binding proteins, 
which represent an additional layer of modulation. Accordingly, deregulated proteolytic 
events have been implicated in many human diseases including cancer, arthritis and 
cardiovascular diseases. 
One such network is the urokinase-type plasminogen activation system that exerts multiple 
functions, both proteolytic and non-proteolytic, in an integrated and reciprocally regulated 
manner. 
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4.1 PLASMINOGEN ACTIVATION SYSTEM 
 
4.1.1 Plasminogen / Plasmin 
 
Plasminogen (Plg) is the zymogen form of the serine protease plasmin (Pli). It is mainly 
synthesised by hepatocytes in the liver2 as well as by other organs and tissues3 and is 
present in the blood stream at high concentration and in interstitial fluids. 
The zymogen is secreted as a single-chain glycoprotein, 791 amino acids long. It is 
composed of seven domains: an N-terminal Pan-apple domain followed by 5 kringle 
domains (KD), containing Lys-binding sites responsible for binding to fibrin and to the cell 
surface, and the C-terminal serine protease domain (SPD), containing the catalytic triad 
(His603, Asp646 and Ser741).  
The conversion of Plg to Pli is mediated by cleavage at the Arg561-Val562 peptide bond4, 
which results in the generation of two polypeptide chains (namely: α and β chain) tethered 
together by two disulphide bonds. The two primary enzymes responsible for the proteolytic 
activation of Plg are tissue-type plasminogen activator (tPA) and urokinase-type 
plasminogen activator (uPA), with the former mainly acting in the blood stream and the 
latter involved in plasminogen activation mostly in extravascular tissues.  
	  
Figure 1: Schematic representation of human plasminogen. 
Human Plg contains an N-terminal Pan-apple domain (PAN), 5 kringle domains (KD-1 to 5) and a SPD at 
the C-terminus. The activation site and the two inter-chain disulphide bonds are depicted. 
 
Once activated, Pli displays a broad trypsin-like specificity and can consequently cleave a 
variety of diverse substrates. Pli has been recognized for a long time as the major 
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fibrinolytic enzyme; indeed, it cleaves fibrin at multiple lysine residues leading to the 
fibrin clots degradation. However, Pli has also been shown to activate and release from the 
extracellular matrix (ECM) several growth factors and chemokines, such as the 
transforming growth factor β (TGFβ)5, 6, the fibroblast growth factor 2 (FGF2)7, 8 and the 
hepatocytes growth factor (HGF)9. Furthermore, Pli can degrade ECM components, 
including laminin, fibronectin (FN)10 and vitronectin (VN)11, and cleave specific 
transmembrane as well as membrane-bound receptors (reviewed in 12). In addition to these 
direct effects, Pli activity is further amplified and diversified by its ability to activate many 
members of the matrix metalloproteinase (MMP) family as the interstitial collagenase 
MMP113 and the two gelatinase MMP2 and MMP914. 
Consistently with its broad substrate specificity, Pli has been implicated in a plethora of 
different biological processes, besides its well-characterized role in fibrinolysis and 
haemostasis. For instance, plasminogen activation has been shown to play a key role in 
tissue remodelling and wound healing, as evidenced by impaired resolution of skin wounds 
in Plg-deficient mice15, and in cell migration and inflammation, as Plg-deficient mice 
display a largely compromised monocytes recruitment in the thioglycollate induced 
inflammation model16.  
 
4.1.2 Regulation of plasmin generation and activity 
 
Being Pli such a broad and potent protease, its temporal activation and spatial localization 
are tightly regulated by a complex network of receptors, activators and inhibitors.  
The main physiological inhibitor of Pli is the serpin α2-antiplasmin (α2AP)17, which forms 
irreversible complex with the protease through an extremely fast kinetic reaction. At a 
lesser extent, Pli is also inhibited by the broad serine protease inhibitor α2-macroglobulin 
(α2M). Remarkably, Pli is resistant to inhibition by both α2AP and α2M when bound to 
the cell surface18. 
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In addition to protection toward inhibition, membrane-bound Plg is more prone to 
activation due to a conformational change occurring upon cell surface binding19, 20. 
Localization at the plasma membrane is therefore of critical importance for Pli generation 
and activity.  
The interaction of Plg/Pli with the cell surface occurs between the Lys-binding sites 
present in the KDs of Plg19, 21 and cell membrane proteins containing a C-terminal basic 
residue22, 23. Many cellular Plg receptors have been identified in the last decades, the 
majority of which are cytoplasmic or nuclear proteins with well-established intracellular 
functions, such as the glycolytic enzyme α-enolase that was among the firsts to be 
identified24. These molecules represent atypical membrane receptors and the mechanism of 
their translocation to the cell membrane is still unknown. In sharp contrast, the latest 
identified Plg-RKT was shown to be a Plg receptor with a C-terminal Lys exposed on the 
cell surface and two predicted transmembrane domains25. Remarkably, Plg-RKT has been 
shown to regulate peripheral blood monocytes migration and invasion in vitro and 
macrophages recruitment at sites of inflammation in vivo26, thus recapitulating a phenotype 
observed in Plg-deficient mice16. 
The key regulators of Plg activation are the two Plg activators: tPA and uPA. They have 
different structures, tissue expression pattern and, indeed, they have been shown to exert 
divergent functions in vivo27, 28. tPA-/- mice display a reduced rate of plasma clots lysis that 
is not observed in uPA-/- mice. On the other hand, inactivation of the uPA gene results in 
phenotypes that are not observed in tPA-/- mice, such as the occasional occurrence of small 
fibrin deposits in the liver and rectal prolapse. Remarkably, however, the double uPA-/-
/tPA-/- mice have much more severe phenotypes compared with single knock-out animals. 
For instance, they have reduced life-span and fertility, extensive spontaneous fibrin 
deposition, a higher incidence of rectal prolapse compared to uPA-/- mice and more 
reduced clots lysis rate than tPA-/- mice28. uPA and tPA can therefore partially compensate 
each other absence and cooperate in diverse vascular as well as extravascular processes. 
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4.2 UROKINASE-TYPE PLASMINOGEN ACTIVATOR SYSTEM 
 
The main components of the uPA system are the serine protease uPA, its cell surface 
receptor uPAR and its inhibitor, plasminogen activator inhibitor 1 (PAI-1). This system 
has been extensively studied over the last decades for its direct link with extracellular 
proteolysis and ECM degradation, in particular in the context of cancer. However, along 
the years a growing body of evidences has documented the existence of a variety of 
functions, which do not require the catalytic activity of uPA but are likewise important in 
physiological and pathological conditions. An emerging “new” component of the uPA 
system is the extracellular protein VN, which has been shown to interact with and 




uPA is secreted  by cells as an inactive polypeptide called single-chain uPA (sc-uPA) or 
pro-uPA.  It is a 411 residues long protein, consisting of the N-terminal growth factor-like 
domain (GFD), a KD domain, a connective peptide containing the activation site and the 
C-terminal SPD, harbouring the catalytic triad (His204, Asp255 and Ser356). The N-
terminal modular region, composed of the GFD and the KD domains, is called amino 
terminal fragment (ATF).  
Zymogen activation occurs through a single specific cleavage after Lys158 mediated by Pli 
that leads to the generation of active two-chain uPA (tc-uPA). In addition, other proteases, 
including cathepsin B29, matriptase30, 31 and hepsin32, have been shown to cleave and 
activate sc-uPA in vitro. Using Plg-/- mice, it has also been reported that glandular 
kallikrein 6 can activate sc-uPA in vivo33. 
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Figure 2: Schematic representation of human uPA. 
The so-called amino terminal fragment (ATF) of uPA is composed of the N-terminal GFD domain and a KD. 
The SPD is located in the C-terminal part of the protein. The activation site and the single disulphide bond, 
tethering the two chains of the active form, are depicted.  
 
uPA expression is highly regulated. Many transcription factors have been identified to 
interact with both promoter and enhancer regions. In addition, instability elements have 
been mapped in the 3’ untraslated region (UTR) of the transcript and are key regulators of 




The glycoprotein PAI-1 belongs to the serpin (serine proteases inhibitor) protein family 
and is the primary and specific inhibitor of both uPA and tPA. Other serpins, such as 
plasminogen activator inhibitor 2 (PAI-2)35, 36 and protease nexin 1 (PN-1)37, have been 
shown to inhibit uPA and tPA in vitro, but with a slower kinetic compared to PAI-138.  
PAI-1 is expressed by many cells in various tissues throughout the body, including 
endothelial cells, adipocytes and vascular smooth muscle cells39-41. It has been suggested 
that the liver may be the primary source of PAI-1 present in the plasma39. However, 
platelets could represent another important source of plasma PAI-1, as it has been recently 
shown that they de novo synthesize and release active PAI-1, in a process that can be 
further stimulated by thrombin42, 43.  
PAI-1 expression is regulated both transcriptionally, by several cytokines (e.g. tumour 
necrosis factor α, TNFα), hormones (e.g. insulin) and growth factors (such as TGFβ and 
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epidermal growth factor, EGF), and post-transcriptionally through the regulation of the 
mRNA stability (review in 34). 
The cDNA of human PAI-1 was cloned in 1986 by four groups44-47. It encodes for a 402 
residues long immature protein with two alternative cleavage sites for the signal peptidase 
in the N-terminal part of the protein. Mature PAI-1 is therefore present in two isoforms, 
having 379 or 381 amino acids44.   
As most serpins, PAI-1 displays a highly ordered globular structure with 3 β-sheets, 9 α-
helices and an exposed peptide loop called reactive centre loop (RCL), which is the key 
element for its inhibitory activity. The RCL contains the P1-P1’ peptide bond (Arg346-
Met347) that acts as substrate for the target protease. The P1 residue is the major 
determinant for PAI-1 specificity; indeed, it has been shown that a basic residue at this 
position in necessary for uPA inhibition48. During the inhibitory reaction, the P1-P1’ 
peptide bond is inserted within the active site of uPA leading to the formation of a 
reversible Michaelis complex between uPA and PAI-1. uPA is therefore able to cleave the 
P1-P1’ bond and is consequently blocked in an irreversible complex through the formation 
of a covalent ester bond between the serine of the active site of uPA (Ser356) and the 
Arg346 of PAI-1 (reviewed in 49). In addition, it has been shown that upon protease 
cleavage, PAI-1 can also behave as a substrate with no inhibitory activity. In this case, 
PAI-1 is inactivated while uPA retains full functionality50. 
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Figure 3: Inhibitory mechanism and dynamics of PAI-1. 
The RCL loop of PAI-1 interacts with the serine in the active site of uPA leading to the formation of a 
reversible Michaelis complex. uPA activity is therefore inhibited through the formation of a covalent 
complex between uPA and PAI-1. Alternatively, PAI-1 is cleaved and inactivated while uPA remains 
catalytically active. The spontaneous latency transition of PAI-1 results in the generation of an inactive latent 
molecule, which does not bind VN and does not inhibit uPA. 
 
A unique feature of PAI-1 compared with all the other serpins is its capability to undergo 
a spontaneous conversion of the active protein into a non-reactive stable form, called 
latent PAI-151. This transition occurs under physiological conditions and is due to the 
insertion of the N-terminal part of the RCL in the central β-sheetA, which causes massive 
structural changes in the protein and the distortion of the key peptide bond P1-P1’. 
Measured half-life for active PAI-1 in vitro is about 1-2 hours at 37°C.  
Binding to VN increases the stability of PAI-1 with about 2-fold increase of the measured 
half-life52. Active PAI-1 binds VN within the N-terminal somatomedin B (SMB) domain 
of the protein53 with a very high affinity interaction (Kd in the subnanomolar range); on the 
contrary latent PAI-1 displays at least 200-fold lower affinity54. Recently, it has been 
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suggested the existence of an additional lower affinity PAI-1 binding site in VN, outside 
the SMB domain55, 56.  
Accordingly with this high affinity, PAI-1 in plasma and in the ECM is present in complex 
with VN57, 58. It has been suggested that PAI-1/VN interaction may actually have a double 





uPAR is a highly glycosylated extracellular receptor bound to the external leaflet of the 
plasma membrane through a glycophosphatidylinositol (GPI) anchor. uPAR cDNA was 
cloned in 199060: it encodes for a precursor protein 335 residues long that is secreted by 
the cells after removal of the N-terminal signal peptide and the C-terminal hydrophobic 
sequence responsible for GPI-anchor attachment61. The mature protein comprises 283 
amino acids and is composed of three homologous LU-domains (called D1, D2 and D3). 
The first crystal structure of soluble uPAR (suPAR) in complex with a uPA-binding 
antagonist peptide was solved in 200562 and showed the expected three-finger fold for the 
LU-domains and extensive interactions among the β-strands of the individual domains 
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Figure 4: The urokinase receptor. 
(A) Schematic representation of the domain organization of uPAR: the three homologous domains (D1-3) are 
tethered to the plasma membrane through a GPI-anchor. (B) Ribbon diagram of the structure of uPAR. 
Interactions among the three domains form a 13-strand antiparallel β-sheet. (C) Equivalent surface 
representation in which carbon and hydrogen atoms are depicted in gray, oxygen in red, nitrogen in blue and 
sulphur in yellow. The hydrophobic central cavity of uPAR responsible for the uPA binding is depicted. 	  
uPAR gene (PLAUR) expression is subjected to a tight regulation. PLAUR promoter 
contains binding sequences for different transcription factors including nuclear factor 
kappa B (NFκB), SP1 and AP2, which mediate the regulation of uPAR gene expression by 
several molecules such as TGFβ, vascular endothelial growth factor (VEGF) and the 
mitogen-activated protein kinase (MAPK) pathway (also known as extracellular signal-
regulated kinase, ERK, pathway) (reviewed in 34). Remarkably, it has been shown that 
uPAR expression is induced in tumour-associated hypoxic conditions through the binding 
of hypoxia-inducible factor 1α (HIF1α) to a hypoxia responsive element present in the 
promoter of the gene63.  Moreover, the stability of the PLAUR mRNA is regulated post-
transcriptionally through the binding of RNA-binding proteins and miRNAs64 to AU-rich 
regions located in the 3’UTR of the transcript. Notably, similar AU-rich regions are also 
present in the 3’UTR of uPA and PAI-1, suggesting the existence of common regulatory 
mechanisms (reviewed in 34). 
 Under physiological conditions, uPAR is only moderately expressed in various tissues and 
organs including lungs, spleen, kidney and liver. On the other hand, organs undergoing 
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massive tissue remodelling are highly positive for uPAR65. Indeed, it has been shown that 
uPAR is present in migrating keratinocytes at the wound edges, but not in the resting 
counterpart in mouse skin65, 66, in trophoblast cells in mouse placenta65 and in human 
gestational tissues67. In addition, uPAR expression was found to be significantly increased 
upon injury, such as traumatic brain injury and cerebral ischemia, where major uPAR-
expressing cells were infiltrating granulocytes, activated macrophages and endothelial 
cells68. uPAR is also expressed in other cells of the immune system, including activated 
neutrophils69, monocytes70 and T-cells71, and in a subset of hematopoietic stem/progenitor 
cells72.  
Many pathological conditions are associated with uPAR overexpression. In particular, a 
huge amount of clinical and experimental data over the last decades has strongly linked 
uPAR, as well as the other components of the uPA system (i.e. uPA and PAI-1), with 
cancer. These molecules are overexpressed in a variety of human tumours including breast, 
lung, colon, ovarian and gastric carcinomas (review in73). Remarkably, they are present not 
only in the cancer cells but also in the tumour stroma: in human colon adenocarcinomas, it 
has been shown that uPAR is expressed by cancer cells at the invasive foci as well as by 
tumour infiltrating macrophages and neutrophils74, 75. In the same tumours, uPA was not 
expressed by malignant epithelial cells but only present in fibroblast-like stromal cells74, 76. 
Similar expression pattern has also been shown for human invasive ductal breast 
carcinomas, where the expression of the uPA system components was only rarely observed 
in cancer cells but rather detected in stromal cells. In fact, uPAR was found to be mainly 
expressed by tumour-associated macrophages77, while myofibroblasts have been identified 
as the primary source of uPA78, 79 and PAI-180. 
It has been shown that the uPA system affects many biological processes involved at 
multiple stages of cancer formation and progression including ECM degradation, cancer 
cell proliferation, migration and intravasation (reviewed in 81). Accordingly, high levels of 
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uPA system components in tumour tissues are significant prognostic factors of poor 




VN was discovered as an adhesive protein capable to support spreading and growth of 
cultured cells82 and called serum spreading factor83. The name “vitronectin” was proposed 
in 1983 because of its ability to bind glass and its adhesive properties84. It is now described 
as a matricellular protein, meaning a protein that does not have a structural function but 
rather acts as modulator of the cell-matrix interface, binding both ECM components and 
cell surface receptors or other proteins present in the pericellular space.  
The primary source of VN is the liver85, even if evidences of extrahepatic synthesis (e.g. in 
brain, adipose tissues, heart and skeletal muscles) have been reported86.  
Mature VN is a highly glycosylated protein, 459 amino acids long. It circulates as a single 
chain (75 kDa) or a disulphide-bridge two-chain form (65 + 10 kDa), which is generated 
upon proteolytic cleavage at the Arg379, by yet undefined enzymes. It is composed of: the 
N-terminal SMB domain (residues: 1-44), followed by a 45RGD motif (i.e. integrin binding 
site), a highly acidic connecting region, harbouring a collagen binding site87 and a 
transglutaminase cross-linking site at Gln9388, and two hemopexin-like domains 
containing an additional collagen binding site89 and the basic heparin binding domain, 






Figure 5: Schematic representation of human VN. 
The N-terminal SMB domain of VN harbours an overlapping epitope for uPAR and PAI-1. Integrins bind to 
the flanking 45RGD motif of the protein that is followed by a highly acidic connecting region and two 
hemopexin-like domains. The basic heparin-binding site and the endogenous cleavage site in the C-terminus 
of the protein are depicted. 
 
VN is present in the circulation at high concentration and also in platelets α-granules, 
where it is found in complex with PAI-190. Most of the plasma VN is in a closed folded 
conformation with limited ligand binding activity91, whereas VN present in platelets and in 
association with the ECM in different tissues is in a high molecular weight multimeric 
form92, 93. VN deposition in normal tissues is limited, but increases in pathological 
conditions, such as atherosclerosis94, liver fibrosis95 and cancer96-98. In addition, VN is 
involved in the early response to acute tissue injury, supporting thrombus formation. 
It has been shown that VN oligomerization can be induced by ligand binding, such as PAI-
199. The resulting VN multimers display a very different reactivity compared to native 
monomeric VN, with enhanced affinity for ECM components and cell surface receptors, 
such as the VN-receptor αVβ3 integrin100. Indeed, multimeric VN has been reported to 
interact with a variety of different proteins and molecules (reviewed in 101). As mentioned 
above, VN interacts with all the core components of the uPA system: it is well-described 
that both uPAR102 and PAI-153 bind to the SMB domain, whereas Plg103 and uPA104 have 
been documented to interact with the heparin binding region of the protein. 
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4.3 uPAR FUNCTIONS 
 
uPAR can orchestrate a variety of different cellular processes in both physiological and 
pathological conditions. uPAR functions are classically categorized as “proteolytic” and 
“non proteolytic” depending on the requirement of the catalytic activity of uPA. 
	  
Figure 6: Overview of the functions of uPAR. 
uPAR functions can be divided in proteolytic and non-proteolytic. On the one hand, it accelerates Plg 
activation through the high affinity binding to uPA. On the other hand, it directly mediates cell adhesion and 
affects intracellular signalling through the direct interaction with the extracellular protein VN and the cross-
talk with transmembrane receptors, such as integrins. 
 
4.3.1 Proteolytic functions 
 
uPAR proteolytic functions were the first to be identified and characterized, as indeed, 
uPAR was discovered in 1985 as the cellular binding protein for uPA105. uPAR binds to 
either sc-uPA or tc-uPA with relatively high affinity (Kd in the low nanomolar range). The 
interaction is mediated by the N-terminal GFD domain of uPA106 and a large hydrophobic 
surface located in the central cavity of uPAR, as clearly shown by the crystal structure of 
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the ATF·uPAR complex solved in 2006107. The binding surface in uPAR comprises 
residues belonging to all the three domains; therefore, an intact and folded receptor is 
necessary for uPA binding108.   
sc-uPA binding to uPAR localizes the zymogen at the cell surface, where it can encounter 
cell-bound Plg. As a consequence, the reciprocal zymogen activation is accelerated109. 
uPAR is thus able to activate and concentrate cell-associated proteolytic activity at specific 
cellular localization, such as at the leading edge of migrating cells110. The ability of uPAR 
to enhance pericellular proteolysis has been documented also in vivo. The combined 
overexpression of uPA and uPAR, but not the individual proteins, in the basal epidermis 
and hair follicles of transgenic mice, has been reported to increase Pli, MMP2 and MMP9 
activity and cause extensive alopecia and epidermal thickening111. These effects are 
mediated only by catalytically active uPA111 through the uPA/uPAR induced Plg 
activation, as the overexpression of the two proteins in Plg-/- mice fails to induce the 
pathological phenotype112.   
However, the study of the real physiological significance of the uPA/uPAR interaction has 
been complicated by the fact that both uPA and uPAR have functions that do not require 
the presence of the binding partner113, 114. The generation of knock-in animals expressing a 
uPAR-binding deficient but catalytically active mouse uPA (PlauGFDhu/GFDhu mice) has 
allowed to reliably dissect the uPA/uPAR contribution115. PlauGFDhu/GFDhu mice remarkably 
differ from uPA-/- mice and display normal life span, tissue regeneration and leukocytes 
recruitment in standard models of inflammation. By contrast, they exhibit fibrin deposits in 
the hepatic tissues accompanied by increased leukocytes infiltration, thus indentifying a 
role of the uPA/uPAR interaction in fibrin surveillance and in the suppression of fibrin-
associated inflammation. 
In addition, uPAR can modulate pericellular proteolysis also through the internalization of 
uPA-inhibitor complexes (i.e. complexes with PAI-1, PAI-2116, 117, and PN-1118). It has 
been shown that the process requires the interaction with members of the low density 
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lipoprotein receptor (LDLR) family119 (including the low density lipoprotein receptor-
related protein-1A and -1B, LRP-1A and LRP-1B, LRP-2 and the very low density 
lipoprotein receptor, VLDLR) and induces the lysosomal degradation of uPA and the 
inhibitor, while uPAR is recycled back to the plasma membrane120. The outcome is 
therefore to favour proteolysis through degradation of inactive complexes and regeneration 
of free uPAR on the cell surface. 
 
4.3.2 Non proteolytic functions 
 
As mentioned above, a variety of uPAR biological functions do not require the presence of 
active uPA. Several studies have clearly documented the existence of uPAR activities 
mediated by binding catalytically inactive uPA variants or due to the overexpression of the 
receptor even in the absence of uPA. These processes have been ascribed to physical 
and/or functional interactions between uPAR and plasma membrane or pericellular 
proteins.  
 
4.3.2.1 uPAR as adhesion receptor 
 
uPAR directly binds to the matrix form of VN, in a RGD- and divalent cation-independent 
process121-123. It may therefore be defined as a bona fide non-integrin VN receptor. 
The interaction between uPAR and the SMB domain of VN has been well-characterized by 
the resolution of the crystal structure of the suPAR·ATF·SMB complex124, in accordance 
with two independent complete alanine-scans of uPAR125, 126 and a non-exhaustive scan of 
the SMB102, 126. The GFD moiety of uPA is inserted in the central cavity of the receptor, 
while the SMB interacts with the outer side, with an epitope comprising residues belonging 
to D1 as well as to the D1-D2 linker region of uPAR. The binding interface consists of an 
arginine recognition site, composed of the residues Phe13, Asp22 and Tyr28 of VN, which 
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interact with the Arg91 of uPAR, and a hydrophobic binding area consisting mainly of 
residues Tyr27 and Tyr28 of VN inserted in a large cavity of the receptor where they 
interact with residues Trp32 and Ile63 of uPAR.  
uPA, or GFD-containing uPA derivatives, ligation greatly increases the affinity of uPAR to 
VN122, 126. It has been proposed that this effect is mediated by receptor conformational 
changes occurring upon uPA binding107, 127 as well as by uPA-induced receptor 
oligomerization and lipid raft partition128-130. 
As mentioned above, also PAI-1 binds to the SMB domain with very high affinity. Indeed, 
the two binding-sites for uPAR and PAI-1 are overlapping and consistently it has been 
shown that the two proteins can compete for VN binding. In line with a much higher 
affinity for the PAI-1/SMB interaction compared to uPAR/SMB131, it has been shown that 
PAI-1 antagonises uPAR-mediated cell adhesion, resulting in cell detachment. Of note, 
this effect is reverted by active tc-uPA, which displaces PAI-1 from VN through the 
formation of the uPA·PAI-1 complex102. In addition, PAI-1 binding to the SMB domain 
also inhibits integrin-mediated cell adhesion, by sterically blocking the binding of integrins 
to the RGD motif of VN132. 
 
4.3.2.2 uPAR as signalling receptor 
 
uPAR lacks transmembrane or cytoplasmic domains, therefore it can not directly transduce 
signals across the plasma membrane. However, a huge amount of independent studies have 
clearly shown that uPAR is a signalling receptor, able to promote cell migration, 
proliferation and survival, independently of uPA catalytic activity. Indeed, uPAR 
overexpression or ligation to uPA and VN can trigger the activation of many intracellular 
signalling molecules, such as the focal adhesion kinase (FAK), the tyrosine kinase Src, the 
small GTPase Rac1 and the MAPK pathway. These signal transduction events are 
mediated by functional and/or direct interaction with other transmembrane receptors, 
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including members of the integrin family, tyrosine kinase receptors (TKRs) and G protein-
coupled receptors (GPCRs) (reviewed in 133).  
It is well-documented that integrins are signalling co-receptors for uPAR. However, it is 
still a matter of debate whether uPAR and integrins interact directly or rather functionally. 
On the one hand, co-localization and co-immunoprecipitation data argue for a physical 
interaction. Consistently, it has been shown that uPAR and integrin co-
immunoprecipitation is inhibited by synthetic peptides corresponding to the integrin 
sequence of the putative binding surfaces (reviewed in 134). On the other hand, experiments 
aimed to specifically detect protein-protein interactions with purified proteins have given 
controversial results. For instance, it has been reported a direct binding between suPAR 
and immobilized Fc-tagged α5β1 integrin135 that could not be reproduced by an independent 
study136. In addition, a complete alanine-scan of uPAR, in a model of uPAR 
overexpression in two different cell lines, has shown that the only important residues for 
uPAR-induced cell spreading and ERK activation are those involved in VN binding. In 
particular, alanine substitution of all the residues previously described as integrin binding 
sites, either individually or in combination, has no effect on the ability of uPAR to induce 
spreading and intracellular signalling125. Along the same line, a recent study from our lab 
has documented the existence of a uPAR-integrin signalling axis which is RGD 
independent and does not require direct physical interactions between uPAR and integrins, 
but rather relies on the plasma membrane tension, generated upon uPAR-mediated 
adhesion to VN, for the transduction of the signal137. 
Despite this controversy about the nature of the interaction between uPAR and integrins, 
many studies document the relevance of this cross-talk.  
The first identified uPAR co-receptor is MAC1 (also know as αMβ2)138. MAC1 is mainly 
expressed in leukocytes, including neutrophils and macrophages, and is involved in cell 
adhesion and chemotaxis in condition of acute inflammation. uPAR-MAC1 interaction has 
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been reported to affect adhesive properties of MAC1, increasing its ability to bind 
fibrinogen139 and to be required for neutrophils chemotaxis in vitro140.  
β3-containing integrins are another class of integrins known to interact with uPAR. β3 
subunits form heterodimers with αV and αIIb subunits. The resulting αVβ3 receptor can bind 
VN as well as FN, while the αIIbβ3 receptor is specific for platelets and is involved in 
physiological processes such as platelet aggregation, through binding to fibrinogen. uPAR-
β3 signalling has been shown to induce cell motility through the activation of Rac1, a small 
GTPase crucial in mesenchymal-type cell migration. In mouse kidney podocytes, it has 
been shown in vitro and in vivo that lipopolysaccharide (LPS)-induced uPAR expression 
triggers αVβ3 activation and increases Rac-driven cell motility and proteinuria141. The 
molecular mechanism of Rac activation by uPAR-β3 has been investigated in cancer cell 
lines. It involves the tyrosine phosphorylation of the adaptor protein p130Cas and the 
consequent formation of the p130Cas-Crk complex that leads to Rac activation through the 
guanidine nucleotide exchange factor DOCK180. This signalling pathway results in 
increased cancer cell migration and invasion142.  
Among the β1-containing integrins, uPAR has been shown to interact with the laminin-5 
receptor α3β1 and with the FN receptor α5β1. Cross-talk with α3β1 modulates matrix 
adhesion and mediates epithelial-to-mesenchymal transition in kidney epithelial cells in a 
Src-dependent process143. Similarly, uPAR-α5β1 has been reported to modulate FN 
adhesion and to increase cell migration135, through the Src/Rac signalling pathway144.  
uPAR-β1 signalling has also been shown to impact on the epidermal growth factor receptor 
(EGFR) activation. In particular, it has been shown that it can promote receptor activation 
and consequently ERK activation, in a FAK-dependent manner. Ultimately, this leads to 
induction of Hep3 human carcinoma cell proliferation in vivo145. In addition, uPAR 
signalling through EGFR has been shown to induce sustained ERK activation in estrogen 
receptor positive (ER+) breast cancer cell lines, thus providing selective advantage when 
cells were deprived of estrogen146.  
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Among the TKRs, uPAR has been reported to interact also with the platelet derived growth 
factor receptor β (PDGFRβ) and to promote proliferation and migration of human vascular 
smooth muscle cells147. 
Another class of uPAR transducers are the GPCRs. Indeed, uPA ligation to uPAR has been 
shown to induce a chemotactic response in different cell lines, independently of its 
catalytic activity148 and in a pertussis toxin sensitive manner149. The signal transducers are 
members of the formyl-Met-Leu-Phe peptide (fMLP) receptor family, which comprises 
three GPCRs: the high affinity fMLP receptor (FPR) and two homologous proteins (FPRL-
1 and FPRL-2). It has been reported that uPA induced migration requires FPRL-1 in 
peripheral monocytes150 and involves both FPRL-1 and -2 in basophils151. fMLP itself is a 
potent leukocytes chemoattractant. Remarkably, fMLP induced directional migration 
requires uPAR152. In particular, a crucial chemotactic sequence in the D1-D2 linker region 
(88SRSRY92) has been identified, as truncated uPAR missing this sequence fails to sustain 
fMLP migration149, 152. Mechanistically, it has been proposed that the conformational 
changes occurring in the receptor upon ATF ligation107, 127 might unmask the chemotactic 
sequence in the D1-D2 linker region, thus leading to the functional interaction with fMLP 
receptors.  
 
4.4 uPAR SIGNALLING AND ADHESIVE FUNCTIONS ARE INTIMATELY 
CONNECTED 
 
The tight connection between uPAR-induced signalling and uPAR-mediated adhesion to 
VN, has been well-documented by a study employing a complete alanine scan of uPAR125. 
uPAR overexpression in two cell lines results in increased VN adhesion accompanied by 
changes in cell morphology (e.g. reduction of cell-cell contact and lamellipodia formation) 
and induction of intracellular signalling (i.e. ERK activation) and cell migration. 
Remarkably, alanine substitution of the residues belonging to the VN binding epitope of 
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uPAR, but not of the residues thought to interact with integrins, strongly affects the ability 
of uPAR to induce these cellular changes. Moreover, the expression of an artificial GPI-
receptor, with no sequence homology with uPAR but sharing the same binding site on VN, 
triggers morphological and cellular changes identical to the WT receptor. This study 
therefore demonstrates that uPAR-VN binding is required and sufficient to induce 
downstream signalling of uPAR125.  
Independent observations corroborate this finding. First of all, it has been reported that the 
interaction between uPAR and VN is also necessary and sufficient to induce cytoskeleton 
rearrangements and cell migration in murine fibroblasts, through the p130Cas/Rac 
signalling pathway153. Moreover, uPAR/EGFR-induced ERK activation in ER+ breast 
cancer cell lines relies on the expression of VN-binding competent uPAR, as the 
expression of a VN-binding deficient mutant  (uPARW32A) fails to activate ERK146. In 
addition, uPAR-β3 mediated cell migration has been shown to be VN-dependent both in 
cancer cell lines142 as well as in kidney podocytes141. In the former study, migration and 
invasion of the breast cancer cell line MDA-MB-231 and of the colon carcinoma cell line 
B3 are strongly impaired in the absence of VN and inhibited by an anti-VN antibody. In 
the latter study, VN-/- mice are protected toward LPS-induced and uPAR/Rac-driven 
proteinuria.     
Taken together, these studies strongly support the concept that uPAR adhesive and 
signalling functions are deeply linked. Two possible, and not mutually exclusive, scenarios 
can be envisioned. On the one hand, uPAR-mediated adhesion to VN could generate 
discrete areas of strong cell adhesion within the cells, thus placing surface receptors, such 
as integrins, in close proximity with their ligands in the ECM. This would therefore trigger 
integrin outside-in signalling. On the other hand, uPAR adhesion to VN could cause 
physical distortion of the focal adhesion components thus modulating their arrangement 
and activity. In this model, the uPAR signal would be transduced mechanically. Supporting 
this view, a recent study from our lab has characterized a novel ligand-independent 
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integrin signalling pathway, in which integrins, in an active conformation, transduce the 
signal even if they are not directly ligated to the ECM. In this process, adhesion is 
mediated by another receptor (i.e. uPAR binding to VN) and the physical contact between 
adhesion and signalling receptors is not direct but is provided by the plasma membrane137.  
 
4.5 CROSS-TALK BETWEEN THE PROTEOLYTIC AND NON-PROTEOLYTIC 
FUNCTIONS OF uPAR   
 
The linker region between D1 and D2 of uPAR is highly susceptible to proteolytic 
cleavage by several proteases including chymotrypsin154 and cathepsin G (87Y↓S and 
92Y↓L)155, various MMPs such as MMP-12 (86T↓Y)156, neutrophil elastase (85V↓T)155, 
human tissue kallikrein 4157, Pli and uPA itself (83R↓A and 89Y↓S)158.  
uPA-mediated cleavage of purified suPAR is a slow kinetic reaction and occurs regardless 
of the binding of uPA to uPAR158, suggesting that the activity of uPAR-bound uPA is not 
primarily directed to the binding uPAR molecule. By contrast, cleavage of cell surface 
uPAR is strongly accelerated and required the interaction between the two proteins159. 
Notably, it has been shown that uPAR on the cell surface can form dimers that 
preferentially localize in specific membrane domains called lipid rafts129. uPAR cleavage, 
catalyzed by uPA in the lipid rafts, was found to be highly accelerated, likely due to the 
high local concentration of uPAR129. In addition, it has been reported that the presence of 
the GPI-anchor changes the exposure of the linker region, being therefore necessary for 
efficient cleavage160.   
In addition to proteolytic cleavage at the D1-D2 linker region, uPAR can undergo a 
process that is called “shedding”, in which the entire protein is released from the cell 
surface. uPAR shedding can be mediated by the GPI-specific phospholipase C and D61, 161 
as well as by proteases that cleave close to the C-terminus of the protein, such as Pli 
(281R↓S)162 and cathepsin G (280Y↓R and 281R↓S)155. 
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Cleavage and shedding of uPAR are irreversible processes that can occur singularly or in 
combination leading to the generation of different forms of suPAR, which indeed can be 
found in vivo163.  
Chymotrypsin cleaved suPAR, but not intact suPAR, displays chemotactic properties in 
different cell lines148, 149. Active suPAR fragments contain the chemotactic sequence 
88SRSRY92 either at their N- or C-terminus149. Consistently, synthetic peptides harbouring 
this sequence (i.e. uPAR(84-95) and (88-95)) are endowed with chemotactic properties, 
which resemble those of uPA149. Their effects are, in fact, pertussis toxin sensitive and they 
have been reported to induce monocytes and basophils migration, through the interaction 
with FPRL-1 and FPRL-1 and -2, respectively150, 151. In addition, uPAR(84-95) has been 
shown to induce hematopoietic stem cell migration in vitro164, via interaction with FPR, 
and to trigger hematopoietic stem cell mobilization in vivo165.    
On the other hand, several independent studies describe the scavenger effect of intact 
suPAR. Indeed, it has been shown that suPAR, by binding uPA, can reduce proliferation 
and invasion of different cancer cell lines both in vitro and in vivo (reviewed in 166). An 
additional mechanism of action for suPAR has been proposed, in which the soluble 
molecule functions by binding uPA/uPAR protein adaptors167. The outcome depends on 
the uPA and uPAR expression of the cells. In uPAR-negative cells, such as HEK293, 
suPAR is a weak signal agonist able to induce ERK activation. By contrast, in cells 
expressing uPA and uPAR, such as MDA-MB-231, it behaves as a negative regulator of 
ERK activation, cell proliferation and invasion, presumably displacing uPA/uPAR from 
adaptor proteins. Notably, cleavage of suPAR by chymotrypsin increases its signalling 
promoting activity and reverts its inhibitory functions167.  
On the cell surface, uPAR shedding reduces the number of receptor molecules, while 
cleavage results in the generation of a truncated D2D3 surface receptor. Truncated uPAR 
can not interact with uPA108, 158, therefore it can no longer promote pericellular proteolysis. 
Similarly, VN binding and the interaction with integrins are also abolished upon receptor 
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cleavage152, 168-170. On the other hand, uPAR cleavage has been shown to be necessary for 
fibroblast differentiation in myofibroblasts171 and for ERK activation in uPA mediated cell 
migration172. 
Taken together, these data suggest the possibility that the activity of uPAR is subjected to a 
feedback regulation by extracellular proteolysis. On the one hand, uPA activation can 
result in receptor cleavage and therefore negatively regulates uPAR binding to uPA, 
uPAR-mediated VN adhesion and consequently uPAR-integrin intracellular signalling, 
thus representing a potential negative feedback regulation of the uPAR activities. On the 
other hand, receptor cleavage and shedding have been shown to generate fragments as well 
as to unmask epitopes endowed with chemotactic and signal agonist properties, therefore 
representing a possible positive loop. Indeed, uPA activation and subsequent uPAR 
cleavage have been proposed as the molecular switch regulating the different activities of 
uPAR. Similarly, Pli, generated in the uPAR-dependent proteolytic cascade, may have a 
dual role: behaving as a negative regulator, cleaving uPAR and VN, or being a positive 
regulator, activating and releasing growth factors from the ECM. In this scenario, the 
capability of uPAR to accelerate and localize the activation of Plg and sc-uPA is not only a 
way to enhance pericellular proteolysis but is also a key factor in the regulation of the 
multiple uPAR functions. 
 
4.6 OBJECTIVES OF THIS STUDY 
 
The different uPAR functions have been extensively studied and are well characterized. 
However, some aspects of the cross-talk between proteolytic and non-proteolytic functions 
are still not fully understood.  
In particular, little is know about how plasminogen activation affects uPAR-VN interaction 
and therefore uPAR-mediated cell adhesion to VN. More broadly, the impact of the uPAR 
proteolytic function on the ligand binding capability of VN is still poorly documented. It 
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has been shown for long time that both uPA and Pli may cleave uPAR and in addition Pli 
can cleave VN at multiple locations. It has been suggested that this may represents a 
negative feedback regulation, but the existence and the mechanism of such loop have not 
been characterized experimentally.  
On the other way around, it is still unclear what is the role of the uPAR-VN interaction in 
the plasminogen activation system. The binding of uPA to uPAR enhances the receptor 
affinity for VN, thus potentially localizing active proteases at specific sites of action. 
However, VN also binds and stabilizes active PAI-1 and remarkably uPAR and PAI-1 
binding to the SMB domain of VN are mutually exclusive. How all these binding 
interactions are connected and how they do operate both in physiological and pathological 
conditions are still partially understood aspects. 
In this context, the aim of the present work is to specifically study the cross-talk between 
uPAR-induced extracellular proteolysis and uPAR-mediated cell adhesion to VN, focusing 
on the role of the uPAR-VN interaction.  
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HEK293 Flp-In T-REx cells, pcDNA5/FRT/TO vector and pOG44 vector were purchased 
from Invitrogen. Human VN urea-purified was obtained from Promega and human FN 
from Trimital. Fugene 6 was obtained from Roche. Human Glu Plg, human Pli and human 
α2AP were purchased from Molecular Innovations. Aprotinin and anti-vinculin antibody 
(hVIN-1) were purchased by SIGMA. Anti-phosphorylated p130Cas antibody (cat no. 
4011) was from Cell Signalling Technology. Anti-uPAR monoclonal antibodies R2 and R3 
are a kind gift of Dr. Gunilla Hoyer-Hansen (Finsen Laboratory, Denmark). GFD was 
kindly provided by Dr. Steve Rosenberg. sc-uPA was kindly provided by Dr. Jack Henkin 
(Abbott Laboratories, Abbott Park, IL). To obtain active tc-uPA, sc-uPA was incubated 
with Pli (100:1, w:w ratio) for 30 minutes at 37°C and Pli was subsequently inhibited with 
an excess of α2AP. PAIWT, PAIR346A, PAI-1R103A/M112A/Q125A, uPA·PAI-1 complex and sc-
uPAS356A were kindly provided by Dr. Peter A. Andreasen (University of Aarhus). sc-
uPAS356A was activated as described above for sc-uPA WT. Monomeric suPAR was kindly 
provided by Dr. Michael Ploug (Finsen Laboratory, Denmark). The monoclonal antibody 
(mAb) 8B12 is a competitive antagonist of the uPAR-VN interaction. Briefly, it has been 
generated using an engineered uPAR variant as antigen and its epitope includes the Arg91 
of uPAR (unpublished data). 
 
5.2 CELL CULTURE AND TRANSFECTIONS 
 
NCI-60 panel cell lines were grown in RPMI 1640 supplemented with 10% FBS, 100 
U/mL penicillin, 100 U/mL streptomycin and 5 mM L-glutamine. HeLa cells were grown 
in MEM supplemented with 10% FBS, 100 U/mL penicillin, 100 U/mL streptomycin, 1 
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mM sodium pyruvate and 0.1 mM non-essential amino acids. Human embryonic kidney 
(HEK293) Flp-In T-Rex cells were cultured in DMEM supplemented with 10% FBS, 100 
U/mL penicillin, 100 U/mL streptomycin, 5 mM L-glutamine, 15 µg/mL blasticidin and 
100 µg/mL zeocin. Chinese hamster ovary (CHO) Flp-In cells were grown in Ham's F12 
medium supplemented with 10% FBS, 100 U/mL penicillin, 100 U/mL streptomycin, 5 
mM L-glutamine and 100 µg/mL zeocin. All cell lines were cultured at 37°C in 5% CO2.  
The Flp-In system is an easy tool for the generation of isogenic stable cell lines without the 
need of clones selection. In addition, the Flp-In T-REx system allows for a tetracycline-
induced expression of the construct of interest. Cells were co-transfected with Flp-In 
expression vectors (pcDNA5/FRT/TO vectors) and the Flp-recombinase vector (pOG44) 
with a 1:10 (weight/weight, w:w) ratio, using Fugene. Selection of stable transfectants was 
performed by substituting zeocin with hygromycin B in the culture medium, at the final 
concentration of 150 µg/mL for HEK293 cells and 500 µg/mL for CHO cells.  The co-
transfection leads to the integration of a single copy of the expression vector to the same 
genomic position in every cell and therefore ensures comparable gene expression and 
avoids potential artefacts due to vector random insertion. Expression in HEK293 Flp-In T-
REx was induced by adding tetracycline at the final concentration of 1 µg/mL to the 
culture medium overnight (O/N). 
 
5.3 EXPRESSION VECTOR CONSTRUCTION 	  
pcDNA5/FRT/TO-uPARWT, pcDNA5/FRT/TO-uPARR83A, pcDNA5/FRT/TO-uPARR89A 
and pcDNA5/FRT/TO-uPARR91A have already been described125. pcDNA5/FRT/TO-
uPARR83/89A and pcDNA5/FRT/TO-uPARW32A/R91A were made by site-directed 
mutagenesis as previously described125. 
Generation of pcDNA5/FRT/TO-VN-His and pcDNA5/FRT/TO-VNG46A-His has already 
been described137. pcDNA5/FRT/TO-VNR45A-His was generated in a two-step overlapping 
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PCR procedure. Firstly, pcDNA5/FRT/TO-VN-His was amplified with oligos 
hVnu/R45AR and R45AF/HISNOTR. Secondly, the two PCR products were mixed, co-
amplified using oligos hVnu /HISNOTR and cloned BamHI/NotI in pcDNA5/FRT-TO.  
The expression vectors for recombinant proteins tagged with a human immunoglobulin G 
(IgG) constant region (Fc) are based on the pcDNA5/FRT/TO-hFc plasmid125, however, a 
number of modifications was introduced to facilitate the shuffling of different coding 
regions as well as to improve protein yields. Firstly, an XhoI restriction site, located in the 
vector sequence downstream of the Fc coding region, was destroyed by site-directed 
mutagenesis using oligos dXu/dXd. Secondly, a linker encoding a cleavage sequence for 
the PreScission protease, made by annealing oligos PreF/PreR, was inserted in the XhoI 
site located at the signal peptide/Fc junction. Since the removal of the intron present in the 
Fc region of the construct was found to increase the yield of recombinant protein (our 
unpublished observations), the vector was transfected into CHO cells, RNA extracted, 
reverse transcribed. The cDNA was then amplified with oligos hVNukpn/FcNr and cloned 
KpnI/NotI into pcDNA5/FRT-TO (Invitrogen corp.) to generate pcDNA5/FRT/TO-Fc. 
pcDNA5/FRT/TO-VN(1-64)-Fc, pcDNA5/FRT/TO-VN(1-64)R45A-Fc, pcDNA5/FRT/TO-
VN(1-64)G46A-Fc were generated amplifying pcDNA5/FRT/TO-VN-His, 
pcDNA5/FRT/TO-VNR45A-His and pcDNA5/FRT/TO-VNG46A-His, respectively, with 
oligos hVNuKpn/VN64DX and cloning the product KpnI/XhoI in pcDNA5/FRT/TO-Fc. 
To introduce the K78Q mutation in the tag, pcDNA5/FRT/TO-VN(1-64)-Fc was amplified 
using oligos FcSuKQ/FcNr and the PCR product was digested XhoI/NotI and cloned in 
pcDNA5/FRT/TO-VN(1-64)-Fc, pcDNA5/FRT/TO-VN(1-64)R45A-Fc to generate 
pcDNA5/FRT/TO-VN(1-64)-FcK78Q and pcDNA5/FRT/TO-VN(1-64)R45A-FcK78Q, 
respectively. pcDNA5/FRT/TO-VN(1-66)-Fc has already been described125, vectors 
carrying single-point mutations were generated by site-directed mutagenesis.  
To generate pcDNA5/FRT/TO-VN(1-45) and pcDNA5/FRT/TO-VN(1-66), 
pcDNA5/FRT/TO-VN(1-66)-Fc was amplified with oligos hVNuKpn/VN45RN and  
	  42	  
hVNuKpn/VN66RN respectively, digested KpnI/NotI and cloned in pcDNA5/FRT/TO-
VN(1-64)-Fc. 
To obtain pcDNA5/FRT/TO-VN(1-61)-EK-hFc, pcDNA5/FRT/TO-VN(1-64)-hFc was 
amplified with oligos hVNuKpn and VN61EKR, digested KpnI/XhoI and cloned in 
pcDNA5/FRT/TO-hFc.  
Construct encoding human suPAR tagged with an Fc, pcDNA5/FRT/TO-uPAR-Fc, was 
made by amplification of a full-length uPAR cDNA with oligos URskF/UpreR2D and 
cloning KpnI/XhoI in pcDNA5/FRT/TO-Fc. To obtain mutant uPAR-Fc constructs, 
pcDNA5/FRT/TO-uPARR83/89A and pcDNA5/FRT/TO-uPARW32A/R91A were amplified with 
oligos urskf/upre2d and cloned KpnI/XhoI in pcDNA5/FRT/TO-Fc to generate 
pcDNA5/FRT/TO-uPARR83/89A-Fc and pcDNA5/FRT/TO-uPARW32A/R91A-Fc, respectively. 
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VN64DX: 5’-GGCTCGAGCTCCTCGCCATCGTCATA-3’ 
FcSuKQ: 5’- GGCTCGAGGGCAGTGGACCCCAATCTTGTGACAAAACT-3’ 
VN45RN: 5’-CCGCGGCCGCTTAGCGAGTCACTTGGGGCTT-3’ 







5.5 EXPRESSION AND PURIFICATION OF RECOMBINANT PROTEINS  
 
The expression vectors described above were transfected into CHO Flip-In cells 
(Invitrogen Corp.) and the recombinant proteins expressed under serum-free conditions as 
previously described125, 173. Recombinant proteins tagged with Fc were purified from the 
conditioned media by standard Protein A affinity chromatography and dialyzed extensively 
against phosphate buffered saline (PBS). His-tagged proteins were purified by immobilized 
metal-affinity chromatography and dialyzed extensively against PBS. 
 
5.6 TIME-LAPSE IMAGING  
 
Time-lapse live cell imaging was performed at 37°C, 5% CO2 with an inverted microscope 
(IX80, Olympus) equipped with an incubation chamber (OKOlab). 12-well-plates were 
coated with recombinant VN (5 µg/mL) O/N at 4°C and then blocked with 5% heat 
inactivated bovine serum albumin (BSA) in PBS for 1 h at 37°C. 293/uPAR cells (250.000 
cells/well) were plated in Opti-MEM® supplemented with 100 U/mL penicillin, 100 U/mL 
streptomycin and 1 µg/ml tetracycline. 2 h after seeding, sc-uPA was added to a final 
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concentration of 10 nM and about 1 h later Plg was added to 30 nM. Cells were imaged at 
regular intervals (2 minutes) using a 20x objective.  
For cell migration experiments, 293/uPAR cells were plated and allowed to adhere as 
described above. After about 2 h of adhesion, cells were treated with 10 nM sc-uPA, PAI-
1, uPA·PAI-1 or vehicle and imaged at regular intervals (5 minutes) using a 10x objective. 
Cell migration was quantified by manual tracking using ImageJ software and the “manual 
tracking” plugin. To obtain a time-resolved quantification of cell velocity, for every time-
point, we calculated the average migration speed over the 30 minutes preceding the time 
point and followed 50 or more individual cells per condition. Adjustment of 
brightness/contrast was done with ImageJ and applied to the entire image.  
 
5.7 DIFFERENTIAL INTERFERENCE CONTRAST (DIC) MICROSCOPY 
 
Adherent cells were fixed with 4% paraformaldehyde (PFA) in PBS for 10 minutes at 
room temperature (RT). Fixed cells were washed with PBS and DIC imaging of cells was 
performed using an inverted microscope Olympus IX81. Cells were viewed through a 
high-aperture 60x objective lens (UIS2 60x TIRFM PlanApo N, NA 1.45; Olympus). 
Images were acquired using Hamamatsu Orca-ER digital camera with the software 
Metamorph 7.5.6.0. Cell-matrix contact area was quantified using ImageJ. Adjustment of 
brightness/contrast was done with ImageJ and applied to the entire image.  
 
5.8 CELL LYSIS AND WESTERN BLOTTING  
 
Cells were lysed directly on the culture dish in hot Laemli buffer. Equal volumes were 
separated by Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis (SDS-
PAGE) and probed as indicated.   
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5.9 LABEL-FREE REAL-TIME CELL-BASED ASSAY (RTCA) EXPERIMENTS  
 
The RTCA technology is a label-free system that allows for real-time monitoring of 
cellular events. The instrument measures electrical impedance through microelectrodes 
located at the bottom of each well. Cells attached on the electrode alter the local ionic 
environment at the electrode/medium interface and therefore cause an increase of electrode 
impedance. The electrical impedance measured for the cell population in the well is the 
sum of mainly two contributions: on the one hand it reflects the number of cells that are 
attached to the electrode (i.e. the more they are, the higher is the impedance), on the other 
hand it depends also on the quality and quantity of cell-electrode interactions (e.g. the 
more cells spread, the larger is the increase in impedance). Accordingly, electrical 
impedance can be employed to follow many cellular processes such as cell proliferation, 
adhesion and spreading. The read-out of the machine is a dimensionless parameter called 
cell index that is defined as the relative change in measured impedance at a given time-
point respect to the background measurement.   
RTCA experiments were conducted as described below. 96-well E-plates (Roche Corp.) 
were coated with FN (10 µg/mL), recombinant VN or VN variants (5 µg/mL) O/N at 4°C. 
Non-specific binding sites on the electrode surface were saturated with 5% BSA in PBS 
for ≥ 1 h at 37°C. Cells (15000 cells/well) were plated in serum-free Opti-MEM® medium 
supplemented with 100 U/mL penicillin, 100 U/mL streptomycin and 1 µg/mL 
tetracycline. To reduce the so-called edge well effect, the plate was left outside the 
incubator for 15 minutes after cell seeding to allow the cells to attach. Subsequently, the 
plate was transferred to the real time cell analyzer instrument (RTCA, xCELLigence SP, 
Roche Corp.) located in a humidified cell culture incubator  (37˚C and 5% CO2) and the 
impedance was measured at regular intervals. Cells were subjected to one or more 
treatments and the times at which treatments were performed are depicted in the graphs by 
vertical lines. Reagent concentrations were the following: 10 nM sc-uPA, tc-uPA, GFD, 
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PAI-1 and uPA·PAI-1, 30 nM Plg and Pli, 100 nM α2AP. To calculate the normalized cell 
index, all the measured cell indexes were divided over the cell index recorded in the same 
well at the time of the first treatment. This normalization reduces variability caused by the 
number of cells seeded in the individual wells, making the normalized cell index more 
comparable between the wells. 
 
5.10 VN FRAGMENTS RELEASE EXPERIMENTS 
 
For 293/uPAR cells release experiments, 12-well plates were coated with VN (5 µg/mL) 
O/N at 4°C and residual binding sites saturated with blocking buffer (5% heat-inactivated 
BSA in PBS) for 1 h at 37°C.  293/uPAR cells (500.000/well) were seeded in Opti-mem® 
and allowed to adhere for about 2 h before further treatments. The final concentrations of 
reagents used in the release experiments were: 10 nM sc-uPA and tc-uPA, 30 nM Plg and 
Pli, 100 nM α2AP and 300 nM aprotinin. The antagonists GFD (300 nM) and the mAb 
8B12 (30 µg/mL) were added to the cells 30 minutes prior to the addition of proteases. The 
conditioned media were harvested 2 h after treatment, filtered and added 
phenylmethanesulfonylfluoride (PMSF) to 1 mM.  
For release experiments conducted using the NCI-60 cell lines, 48-well plates were coated 
with VN as described above. 50.000 cells/well were seeded in Opti-mem® in the presence 
or absence of 30 nM Plg and 100 nM α2AP. Supernatants were collected after 16 h and 
treated as described above. 
 
5.11 MATRIX-ASSISTED LASER DESORPTION/IONIZATION TIME OF FLIGHT 
(MALDI-TOF) MASS SPECTROMETRY (MS) 
 
MALDI-TOF MS is a soft ionization technique that allows for the determination of intact 
proteins or peptides molecular weight. The read-out of the machine is a mass over charge 
	   47	  
ratio (m/z). Since ions analyzed are usually monocharged, it coincides with the molecular 
weight (MW) of the peptides. In particular, when experiments are carried out in linear 
mode, as in the experiments described below, the obtained mass values correspond to the 
average molecular mass. 
For in vitro fragments generation, VN (Promega) or recombinant VN variants were 
subjected to proteolytic digestion with Pli or tc-uPA for 2 h at 37°C. Where indicated a 3-
fold excess of uPAR-Fc was added to the reaction mixture. The reaction was carried out in 
PBS with a 10:1 (weight/weight, w/w) ratio of VN to protease. Two picomoles of digested 
VN were deposited onto a MALDI plate and allowed to air-dry. Matrix (5 mg/mL α-
cyano-hydroxy-cinnamic acid in 50% acetonitrile /0.1% trifluoroacetic acid) was spotted 
directly on top.  
Regarding the analysis of human urine samples, a pull-down assay using HF6-conjugated 
beads was performed. Urine samples were supplemented with Tris-HCl pH 7.5 at a final 
concentration of 50 mM and PMSF at a final concentration of 1 mM and VN fragments 
were immunoprecipitated using HF6-conjugated beads. Eluted material was desalted using 
C8 zip-tip before spotting it on the MALDI plate. 
Mass spectra were acquired in linear mode on a 4800 MALDI-TOF/TOF mass 
spectrometer (Applied Biosystems, Foster City, CA) equipped with a 336 nm nitrogen 
laser. Ions were accelerated with a 20 kV pulse. Spectra were generated in the mass range 
2–20 kDa by averaging 40 sub-spectra for each of 25 randomized positions within the spot 
(1000 spectra/spot). Laser intensity was set at 4000 V to optimize the signal-to-noise (S/N) 
ratio and the resolution of mass peaks of the analyte. 
 
5.12 ANTIBODIES GENERATION 
 
Five 2-month-old male C57Bl/6 VN-/- mice were immunized by intraperitoneal (IP) 
injection with 100 µg VN(1-66)/hFc in 200 µL immunogen in PBS and 100 µL of 
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Complete Freund’s Adjuvant (CFA). The immunized animals were boosted 3 times, at 3-
week intervals, by IP injection of 100 µL VN(1-66)/hFc in 200 µL of 1:1 emulsion 
between 100 µL immunogen in PBS and 100 µL of Incomplete Freund’s Adjuvant (IFA). 
After a 7-week rest period and 4 days before the fusion, the two best mice, chosen 
depending on sera titration (see Screening of sera/supernatants), were subjected to a final 
pre-fusion IP boost using 200 µg VN(1-66)/hFc in 200 µL PBS.  
Spleens were removed and the splenocytes fused to the mouse SP2/0 myeloma cell line by 
the polyethylene glycol method using standard procedure174. After fusion, the cells were 
cultured for one day in non-selective medium (Iscove, 10% FBS, 1xHFCS) and then plated 
in 96 well-plates (35000 splenocytes/well) in selective HAT medium (Iscove, 1xHAT) 
supplemented with 1xHFCS (Hybridoma Fusion and Cloning Supplement, Roche Corp.). 
Hybridomas positive for the production of immunoglobulin specific for the antigen were 
identified by Time-Resolved Fluorescence Immunoassay (TR-FIA, see Screening of 
sera/supernatants), expanded in 12-well plates and frozen. Selected hybridomas were sub-
cloned by limiting dilution in 96-well plates. Cells were plated in HT medium (Iscove, 
1xHT) supplemented with 1xHFCS at a density ranging from 0.4 to 0.1 cells/well. When 
necessary, the sub-cloning procedure was repeated until all sub-clones scored positive by 
TRF-assay. The isotypes of the immunoglobulin produced by the different hybridomas 
were determined using a commercially available ELISA kit (Mouse Immunoglobulin 
Isotyping ELISA Kit, BD Pharmingen Corp.). In this way, three IgG1 monoclonal 
antibodies (namely HU3, HF6 and IO35) with non-overlapping epitopes were obtained. 
 
5.13 TIME-RESOLVED FLUORESCENCE BASED ASSAYS 
 
Immunoassays and binding assays were performed using Eu3+-labeled reagents as 
detection system. This technology has many advantages compared to the conventional 
fluorescence. Firstly, Eu-complexes display higher sensitivity and can be used to measure 
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Eu3+ down to the sub-picomolar range (10-13 moles/L). Secondly, the use of Eu leads to 
very low background signal, due to a long decay time of the emitted fluorescence. This 
allows for a delayed measurement after the excitation and therefore for the exclusion of the 
background short-lived autofluorescence signals coming from solvents and reagents. In 
addition, Eu3+ ion is endowed with an extremely large Stokes shift (very different 
excitation and emission wavelengths) and a very narrow emission band, which contribute 
to increase the S/N ratio. In particular, we took advantage of the DELFIA® (dissociation-
enhanced lanthanide fluorescence immunoassay) technology. In this system, the Eu3+ ion is 
dissociated from the labeled antibody bound to the solid phase by addition of a low pH 
chelating detergent solution (called DELFIA enhancement solution) to form a new highly 
fluorescent complex in a micellar solution, which ultimately leads to a further increase in 
sensitivity. 
 
5.13.1 Screening of sera/supernatants 
 
Black 96-well plates (MAXI-SORP, NUNC Corp.) were coated with SMB-GFP, 1 µg/mL 
in coating buffer (50 mM sodium carbonate, pH 9.6). After washing with PBS containing 
0.1% Tween-20 (PBS-T, wash buffer), wells were blocked with 2% BSA in PBS, washed 
and incubated with sera/cell culture supernatants, properly diluted in 1% BSA in PBS. 
Bound mouse immunoglobulins were detected using a Eu3+-labeled anti-mouse Fc 
antibody (1:5000, Perkin Elmer Corp.). Before reading the plates, wells were extensively 
washed and incubated with DELFIA enhancement solution (Perkin Elmer Corp.). The 
Eu3+-label was detected by measuring time-resolved fluorescence intensity using an 





5.13.2 Antibody epitope mapping experiments 
 
Black 96-well immunoplates were coated with the monoclonal antibodies of interest (0.5 
µg/mL) diluted in coating buffer O/N at 4°C. After washing with PBS-T, plates were 
blocked with The Blocking Solution (CANDOR Bioscience GmbH) for ≥ 2 h at RT 
shaking. Wells were incubated with the antigen VN(1-66)/Fc WT or carrying point 
mutations. Antigen binding was detected by incubation for 1 h at RT with Eu3+-labeled 
anti-human Fc antibody (1:1000, Perkin Elmer Corp.). The Eu3+-label was detected as 
described above. 
 
5.13.3 Immunoassays for the detection of N-terminal SMB-containing VN fragments 
 
We developed two immunoassays (namely HU3/HF6 and HU3/IO35) for the detection of 
N-terminal VN fragments. They have slightly different specificity: HU3/IO35 assay 
detects only fragments longer than 1-65; on the contrary, HU3/HF6 can detect also shorter 
fragments (e.g. 1-45). 
Black 96-well immunoplates were coated with the monoclonal antibody HU3 (0.5 µg/mL) 
diluted in coating buffer at 4˚C O/N. Plates were washed with PBS-T and blocked with 
The Blocking Solution for ≥ 2 h at RT shaking. After washing with PBS-T, wells were 
incubated with samples (loaded in duplicate) properly diluted in PBS-T. The binding was 
allowed to occur 1-2 h at RT shaking. Bound VN fragments were detected by sequential 
incubations with biotinylated HF6 or IO35 monoclonal antibody (0.5 µg/ml) and Eu3+-
labelled Streptavidin (1:10000, Perkin Elmer Corp.) for 1 h at RT shaking. The Eu3+-label 
was detected as described above. 
For HU3/HF6 assay, VN(1-61) was used as standard and a 7-point standard curve was 
made starting from 0.12 nM with a 2-fold dilution. When comparing HU3/HF6 and 
HU3/IO35 assays, the standard curve was done using conditioned medium of CHO cells 
	   51	  
expressing VN(1-66). Background binding was measured in wells incubated with PBS-T 
and was subtracted from the total binding. The standard curve was fitted to the 
experimental data and the unknown concentrations were interpolated by non-linear 
regression using the log[agonist] vs. response – variable slope (four parameter) algorithm 
and the GraphPad Prism (V6.0b) software. 
 
5.13.4 Binding assays 
 
Binding assays were performed in black 96-well immunoplates coated with recombinant 
VN (5 µg/mL) in coating buffer at 4˚C O/N. Plates were washed with PBS-T and the 
remaining binding sites saturated with The Blocking Solution for ≥ 2 h at RT. After 
washing with PBS-T, wells were incubated with the indicated concentrations of uPAR-Fc 
or uPARW32A/R91A-Fc diluted in PBS-T in the presence of 10 nM sc-uPA and tc-uPA or 
with a dilution curve of the different ligands. Where indicated a pre-incubation with 10 nM 
PAI-1 or PAI-1 mutants was performed at 4°C for 2 h. After 1-2 h at RT, unbound 
reagents were removed by rinsing with wash buffer. The binding of the different uPAR-Fc 
variants was detected by incubation with a Eu3+-labeled anti-human Fc antibody (1:1000). 
When comparing untagged and Fc-tagged uPAR, the extent of uPAR binding to VN was 
evaluated by subsequent incubation with the anti-uPAR monoclonal antibody R2 (0.5 
µg/mL) and Eu3+-labeled anti-mouse Fc antibody (1:5000). The Eu3+-label was detected as 
described above. Background binding was measured in wells incubated with no receptor 
and was subtracted from the total binding. 
uPAR-Fc binding to sc-uPA was assayed as described for binding to VN, using 1 µg/mL 





5.14 PREPARATION OF CALIBRATOR SAMPLES 
 
Four different “calibrator” urine samples were prepared. The first three (termed “High”, 
“Medium” and “Low”) were made by pooling 20 urine samples of colorectal cancer 
patients falling within the upper quartile (High), lower quartile (Low) or close to median 
(Medium) of all the measurements, n = 165 (data not shown). A fourth calibrator, 
“Matrice”, is a single urine sample provided by a young healthy volunteer. All four 
calibrators were aliquoted and stored at -80˚C. 
 
5.15 GENERATION OF THE VN(1-61) STANDARD 
 
To obtain a highly pure standard for VN fragments immunoassays, we generated a chimera 
protein composed of the first 61 amino acids of human VN fused with the human Fc region 
with a cleavage site for enterokinase located in the linker region between VN residues and 
the Fc region (see Expression vectors construction section for the generation of 
pcDNA5/FRT/TO-VN(1-61)-EK-hFc vector and Expression and purification of recombinant 
proteins section for the purification of Fc-tagged proteins). The purified protein was 
digested with enterokinase and the VN(1-61) fragment was purified by high-performance 
liquid chromatography (HPLC). The concentration of purified VN(1-61) fragment (>90% 
purity as estimated by HPLC and SDS-PAGE, data not shown) was accurately determined 
by amino acid analysis. This reference protein was used to generate standard curves and 
for spike in experiments.  
 
5.16 CREATININE ASSAY 
 
For creatinine assay, the ParameterTM kit from R&D Systems was used according to 
manufacturer’s instructions. 
	   53	  
6. RESULTS 
 
6.1 NEGATIVE FEEDBACK BETWEEN uPAR PROTEOLYTIC AND NON-
PROTEOLYTIC FUNCTIONS 
 
6.1.1 Plasminogen activation exerts a negative feedback on cell adhesion to VN   
 
To investigate existence and mechanisms of feedback loops between the function of uPAR 
in extracellular proteolysis, cell adhesion and signalling, we used uPAR overexpressing 
HEK293 (293/uPAR) cells as model system. HEK293 cells express neither uPAR nor 
uPA122 and are therefore a suitable model to perform structure-function studies. It has been 
previously shown that the ectopic expression of uPAR in HEK293 cells leads to extensive 
changes in cell morphology, increase in cell adhesion to VN and basal random cell 
migration and activation of migratory and proliferative signalling pathways125, 137. 
To test whether uPAR-initiated proteolysis mediates feedback mechanisms on uPAR-
induced cell adhesion and spreading, we conducted time-lapse microscopy on 293/uPAR 
cells seeded on VN and exposed to consecutive additions of sc-uPA and Plg to trigger the 
plasminogen activation cascade (Fig. 7 and Movie 1). When seeded on VN, 293/uPAR 
cells displayed an adherent phenotype characterized by extensive lamellipodia formation 
that was further enhanced by sc-uPA addition. Treatment with Plg, however, rapidly 
reversed the pro-adhesive effect of sc-uPA as evidenced by lamellipodia retraction and the 
acquisition of rounded cell morphology, similarly to what has previously been reported for 






293/uPAR cells were seeded on VN and imaged by 
time-lapse microscopy. Cells were treated with 
subsequent additions of sc-uPA and Plg and 
representative phase contrast images, taken just 
before and 2 hours after addition of Plg, are shown. 
The complete time-lapse recording can be found as 





To quantitatively analyze the negative feedback, we took advantage of a RTCA 
instrument, which allows for the continuous and non-invasive evaluation of the extent and 
quality of cell-matrix interactions by impedance measurements176 (see material and 
methods for a more detailed description of the technique). The data obtained by RTCA 
analysis (Fig. 8A) closely paralleled the time-lapse microscopy recordings: after an initial 
adhesion phase, treatment with sc-uPA caused a marked increase in cell adhesion that was 
rapidly reverted upon subsequent addition of Plg. The inhibitory effect of plasminogen 
activation on cell adhesion to VN was mediated by cell surface associated Pli and/or tc-
uPA activity as the addition of α2AP, which inhibits free but not membrane bound Pli18, 
had limited effect on the proteolytic feedback. When cells were seeded on FN, the 
triggering of plasminogen activation did not impair cell adhesion, but rather resulted in a 
delayed and transient increase (Fig. 8B). In contrast to VN, the transient increase in FN 
adhesion is mediated by the activity of free Pli as it was fully inhibited by α2AP. 
Figure 7: Effect of plasminogen activation on 
293/uPAR cells morphology. 
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Figure 8: Plasminogen activation exerts a negative feedback on cell adhesion to VN. 
RTCA analysis of 293/uPAR cells seeded in VN- (A) or FN-coated (B) wells is shown. Cell adhesion and 
spreading were followed over time by recording the changes in electrical impedance, named cell index (see 
Material and methods section for a more detailed description of the system). Stippled vertical lines indicate 
the time-points at which the cells were treated. Each condition was recorded in quadruplicates and the 
curves represent the average cell index as a function of time. Cell index values are normalized to the cell 
index measured before the first treatment. Data are from a representative experiment.  
 
It has been shown that uPAR binding to VN is required and sufficient to induce p130Cas 
substrate domain phosphorylation through the Src/FAK signalling pathway125, 137, 142, 153. 
To test the effect of plasminogen activation on p130Cas phosphorylation, we treated 
293/uPAR cells seeded on VN or FN with Pli (Fig. 9). In line with the RTCA data, 
treatment with Pli resulted in a clear reduction of p130Cas phosphorylation when cells 





Figure 9: Plasminogen activation down-modulates uPAR-induced cell signalling on VN. 
293/uPAR cells were seeded on VN- or FN-coated culture plates and allowed to adhere for about 1 hour 
before treatment with 30 nM Pli or vehicle. Cells were lysed at the indicated time points after treatment. 
Lysates were resolved by SDS-PAGE and p130Cas phosphorylation was assayed by immunoblotting. The 
blot is from a representative experiment. 
 
These results document the existence of both positive and negative feedback loops 
between plasminogen activation and cell signalling and adhesion to VN and FN. 
 
6.1.2 The catalytic activity of both uPA and Pli contributes to the negative feedback 
 
The process of plasminogen activation is a reciprocal zymogen activation cascade in which 
the zymogen sc-uPA is converted into active tc-uPA and the zymogen Plg into active Pli, 
thus resulting in the concomitant generation of two distinct serine protease activities. To 
determine which of these activities is responsible for the negative feedback, we analyzed 
the cellular response to the isolated active proteases (Fig. 10). Both sc-uPA and active tc-
uPA stimulated VN-adhesion to a similar extent and with similar kinetics, consistent with 
the fact that both contain the receptor binding GFD domain responsible for inducing 
uPAR-binding to VN123, 126. However, after the initial induction, the adhesion of tc-uPA 
treated cells started to decline as compared to cells treated with sc-uPA, demonstrating that 
the catalytic activity of uPA contributes directly to the feedback. The decline was not as 
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activity of uPA is involved but not sufficient to obtain the full magnitude of the feedback. 
Consistently, the addition of Plg to tc-uPA-treated cells further accelerated the feedback. 
To directly evaluate the contribution of Pli, we first treated cells with GFD to mimic the 
pro-adhesive effect of ligand-occupancy and then challenged the cells with Pli (Fig. 10). 
The treatment with Pli caused a rapid decrease in cell adhesion indicating that the 
proteolytic activity of Pli also contributes directly to the negative feedback. 
	  
Figure 10: The catalytic activity of both uPA and Pli contributes to the negative feedback between 
plasminogen activation and cell adhesion. 
RTCA experiments were conducted with 293/uPAR cells seeded in VN coated wells and treated as reported 
in the figure. A representative experiment is shown.  
 
6.1.3 The negative feedback is partially caused by uPAR cleavage   
 
It has been recognized for a long time that the linker region connecting D1 and D2D3 of 
uPAR is highly susceptible to proteolysis by various proteases including uPA and Pli158, 
159. Since the binding site for VN in uPAR involves determinants in both D1 and D2D3125, 
126, cleavage of the linker region could possibly account for the negative feedback. To 
address this possibility, we generated HEK293 cells expressing a uPAR-variant where the 
reported uPA and Pli cleavage sites (83R↓A and 89R↓S)159 have been disrupted by alanine 































substitution of the arginine residues. The resulting receptor (uPARR83/89A) displayed largely 
intact VN binding that was stimulated by ligand-occupancy similarly to the wild-type 
receptor (Fig. 11). To gauge the role of uPAR cleavage, we therefore compared the effect 
of plasminogen activation on cell adhesion to VN mediated by uPARWT (Fig. 10) and 
uPARR83/89A (Fig. 11).  The onset of the negative feedback mediated by tc-uPA was 
markedly delayed indicating that uPAR-cleavage indeed contributes to the feedback. 
However, the mutational impairment of receptor cleavage did not fully phenocopy the 
effect of treatment with catalytically inactive sc-uPA. Furthermore, the treatment of 
293/uPARR83/89A cells with GFD followed by Pli resulted in a pronounced reduction in VN 
adhesion similar to that observed for 293/uPARWT cells (Fig. 10).  
	  
Figure 11: The cleavage of uPAR contributes partially to the negative feedback. 
293/uPARR83/89A cells were seeded on VN and treated as in Fig. 10. A representative experiment is shown.  
 
Western blotting analysis confirmed that sc-uPA plus Plg, tc-uPA or Pli effectively cleave 
a significant fraction of uPARWT, but not uPARR83/89A (Fig. 12). 
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Figure 12: uPARWT but not uPARR83/89A is cleaved by both uPA and Pli. 
293/uPAR and 293/uPARR83/89A cells were seeded on FN-coated culture plates and allowed to adhere for 1 h 
before treatment with the indicated reagents. After 1 h of treatment, cells were lysed, resolved by SDS-PAGE 
and analyzed by immunoblotting using monoclonal antibodies recognizing different epitopes in uPAR. R2 
binds an epitope in D3 of uPAR and recognizes the full-length receptor (uPAR) as well as the cleaved form 
lacking D1 (D2D3). R3 binds an epitope in D1 and only recognizes full-length uPAR. The blot is from a 
representative experiment and the mobility of molecular weight standards is shown. 
 
These data thus demonstrate that cleavage of uPAR by tc-uPA and Pli is only partially 
responsible for the negative feedback indicating that other functionally relevant uPA/Pli 
substrates are also involved in the process.  
 
6.1.4 Pli cleaves the RGD-motif in VN  
 
Pli has been shown to cleave VN at multiple locations in vitro11, 177 and the treatment of 
VN-coated surfaces with Pli attenuates subsequent αvβ5-dependent adhesion of 
keratinocytes178. Consistent with these observations, we found that pre-treatment of VN 
coated surfaces with Pli, but not with tc-uPA, resulted in a dose-dependent reduction of 
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adhesion as the integrin-mediated adhesion of HeLa cells was also impaired (Fig. 13A). 
The inhibitory effect of Pli was however specific for VN as identical treatments of FN 
failed to modulate subsequent cell adhesion (Fig. 13B).  
Wells coated with VN (A) or FN (B) were 
incubated with a dilution curve of Pli or tc-uPA 
for 1 h at 37˚C prior to cell seeding. After 
washing, 293/uPAR or HeLa cells were seeded 
and their adhesion was followed by RTCA. 
The cell indexes recorded 1 h after seeding are 
shown. Data are reported as percentage of the 
cell index measured in non-pre-treated wells 
and represent the mean ± standard error of the 




To investigate if the reported cleavage sites for Pli in VN were responsible for the negative 
feedback, we seeded 293/uPARR83/89A cells on a recombinant form of VN (VN(1-64)-Fc) 
containing the N-terminal SMB domain responsible for uPAR binding and the flanking 
45RGD-motif interacting with integrin adhesion receptors, but none of the previously 
reported Pli cleavage sites located in the more C-terminal regions (88K↓G, 348K↓K and 


















































Figure 13: Pre-treatment of VN with Pli, 
but not uPA, inhibits subsequent cell 
adhesion mediated by uPAR and integrins. 
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Figure 14: Cartoon illustrating the domain structure of human VN and the VN(1-64)-Fc chimera. 
The N-terminal part of VN contains the SMB domain (residues 1-44) responsible for uPAR and PAI-1 
binding as well as the flanking 45RGD-motif responsible for integrin binding. The remaining C-terminal part 
contains hemopexin-like repeats intersected by a heparin binding site and it is responsible for binding to the 
ECM. The VN(1-64)-Fc chimera contains residues 1-64 of human VN fused to the Fc region of a human IgG 
heavy chain. The location of tc-uPA and Pli cleavage sites experimentally determined in this study are 
indicated in red while previously reported sites are reported in black.  	  
Treatment of cells seeded on this substrate with tc-uPA, or sc-uPA plus Plg, still resulted in 
a robust negative feedback suggesting that the responsible cleavage site(s) are located 
within the N-terminal region of VN (Fig. 15).  
	  
Figure 15: Cleavage site(s) responsible for the negative feedback are in the N-terminal region of VN. 
RTCA experiment was performed on 293/uPARR83/89A cells seeded on VN(1-64)-Fc and treated as reported. 
A representative experiment is shown. 































Pli exhibits broad substrate specificity and cleaves peptide bonds after basic amino acid 
residues (lysine and arginine). To identify the Pli cleavage site(s) in the N-terminal part of 
VN, we individually mutated all basic residues present in this region into alanines, to 
abrogate proteolytic cleavage. VN variants so generated were used as coating substrate in 
RTCA experiments (Fig. 16 and 17). All mutants were comparably proficient in supporting 
uPAR-mediated 293/uPAR cells adhesion with the exception of the R8A mutant (Fig. 17). 
Notably, the R45A mutation was the only that abrogates both cell adhesion inhibition by 
Pli substrate pre-treatment (Fig. 16) and the negative feedback upon plasminogen 
activation (Fig. 17), indicating that cleavage at 45R↓G in VN by Pli might be functionally 
responsible.   
	  
Figure 16: R45A mutation makes VN insensitive to Pli pre-treatment. 
Wells were coated with VN, FN or VN(1-66)-Fc variants and incubated with 30 nM Pli or vehicle for 1 h at 
37˚C prior to cell seeding. Subsequent 293/uPAR cells adhesion was followed by RTCA. The cell indexes 
recorded 1 h after seeding are shown as percentage of the cell index measured in non-pre-treated wells. 
Statistically significant difference between pre-treated and non-pre-treated wells was probed using Student’s 
t-test (* = p<0.05, ** = p<0.01 and *** = p<0.001). Data are from a representative experiment, means ± 
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Figure 17: The R45A mutation in VN strongly impairs the negative feedback. 
RTCA experiments were performed on 293/uPARR83/89A cells seeded on VN(1-66)-Fc mutants and treated as 
reported. A representative experiment is shown. 
 
To confirm this, we treated intact VN with Pli and analyzed the cleavage products by 
MALDI-TOF mass spectrometry (Fig. 18A). The molecular weight of the main peak 
observed in the resulting spectra closely matched that of an N-terminal VN-fragment 
(VN(1-45), theoretical average mass: 5159.71 Da) generated by 45R↓GD cleavage. A peak 
with the same mass, but lower intensity, was also observed in spectra of non-treated VN 
(Fig. 18B), but not in spectra of Pli alone (Fig. 18C) suggesting that VN may be 
particularly prone to hydrolysis at this position and already partially cleaved. The same 
VN-fragment was also observed upon Pli-treatment of VN(1-64)-Fc (Fig. 18D), but not in 
a variant of this chimera (VN(1-64)R45A-Fc) containing an alanine substitution of 45R (Fig. 
18E), conclusively identifying 45R↓GD as a novel cleavage site for Pli in VN. 























Figure 18: Pli cleaves VN in the RGD-motif after Arg45. 
(A) Urea purified VN was incubated with Pli (substrate/enzyme ratio: 10:1 w/w) for 2 h at 37°C and the 
reactions were analyzed by MALDI-TOF mass spectrometry. A representative spectrum is shown. (B, C) 
Representative MALDI-TOF spectra of untreated VN (B) and Pli alone (C). (D, E) Representative MALDI-
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6.1.5 Cleavage of the RGD-motif in VN is responsible for the negative feedback between 
plasminogen activation and cell adhesion  
 
To determine if the observed 45R↓GD cleavage is functionally responsible for the feedback 
between plasminogen activation and cell adhesion to VN, we performed RTCA 
experiments using 293/uPARR83/89A cells seeded on VN and different VN-variants where 
cleavage has been prevented by alanine substitution of 45R in the RGD-motif (see cartoon 
in Fig. 14). Since the 45R→A substitution, introduced to prevent cleavage, also results in 
impaired integrin-binding, we generated a second variant carrying the 46G→A substitution 
that also abrogates integrin binding, but should have limited effect on cleavage.  A 
representative experiment, illustrating the effect of the 45R→A and 46G→A substitutions 
on the proteolytic feedback, is shown in Fig. 19 and the quantified data from multiple 
experiments are presented in Fig. 20A and B.  
	  
Figure 19: R45A mutation in VN strongly impairs tc-uPA mediated negative feedback. 
293/uPARR83/89A cells were seeded on VNR45A or VNG46A and treated with sc-uPA or tc-uPA at the indicated 
time-point (stippled vertical line). A representative RTCA experiment is shown. The time-point (6 h after 
treatment) at which the analysis shown in Fig. 20 was performed is depicted as vertical dashed line. 
 
Introduction of the cleavage-blocking 45R→A substitution in both intact VN and the 
shorter VN(1-64)-Fc chimera significantly and almost completely impaired the proteolytic 
feedback mediated by tc-uPA alone (Fig. 19 and Fig. 20A), demonstrating that the 45R 























cleavage site in the RGD-motif of VN is indeed functionally responsible for the bulk of the 
negative feedback mediated by active tc-uPA. The minor residual feedback observed on 
VN(1-64)-Fc was mediated by cleavage at a lysine residue (78K) located in the Fc-part of 
the chimera. When cells were treated with a combination of sc-uPA, Plg and α2AP (Fig. 
20B), the 45R→A substitution had little effect on the proteolytic feedback on intact VN 
suggesting that other cleavage sites for Pli in VN are also important, or become important 
when the primary cleavage site has been inactivated. Nevertheless, the 45R→A substitution 
did significantly impair the feedback on the shorter VN(1-64)-Fc chimera documenting 
that 45R↓GD-cleavage may indeed contribute to the feedback. As observed for tc-uPA 
alone, the feedback was completely impaired by introduction of the 78K substitution in the 
Fc-tag. Unexpectedly, the control mutation (46G→A) significantly potentiated the negative 
feedback induced by tc-uPA. Although we have not investigated this point further, one 
explanation may be that the wild type 45RGD-motif is partially protected from cleavage 
when bound by integrins. Therefore, the 46G→A mutation may promote cleavage by 
preventing integrin binding.  
	  
Figure 20: Cleavage of VN in the RGD-motif is responsible of the negative feedback. 
RTCA analysis of 293/uPARR83/89A cells seeded on different VN variants and treated with tc-uPA (A) or a 
combination of sc-uPA, Plg and α2AP (B). To merge independent experiments, the cell index measured after 
6 h of treatment is shown as percentage of the one measured for cells seeded on the same substrate, but 
treated with sc-uPA, as depicted in Fig. 19. Dots are data from independent experiments and means ± SEM 
are shown. The significance levels were probed using Student’s t-test. 
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Having identified a VN-variant largely refractory to the proteolytic feedback (VN(1-
64)R45A-FcK78Q, see Fig. 20A and B), we utilized this substrate to reinvestigate the 
contribution of uPAR-cleavage to the feedback. We generated 293 cells expressing uPAR-
variants in which the two published cleavage sites are mutated individually or in 
combination (Fig. 21). This analysis revealed that cleavage both at 83R↓ and 89R↓ 
contribute to the negative feedback and that these sites are the only important ones as the 
alanine substitution of both completely abolished the feedback. 
	  
Figure 21: Cleavage of uPAR by uPA and Pli contributes to the negative feedback. 
RTCA analysis of 293/uPARWT or mutant cells (as indicated) seeded on VN(1-64)R45A-FcK78Q and treated 
with sc-uPA, tc-uPA or with a combination of sc-uPA, Plg and α2AP. Independent experiments were merged 
as described for Fig. 20. 
 
These data thus demonstrate that the proteolytic feedback between plasminogen activation 
and cell adhesion to VN is functionally mediated by cleavage of both VN and uPAR and 
catalyzed by both tc-uPA and Pli. In the process, the cleavage of VN appears to be 
relatively more important than cleavage of uPAR. The main cleavage site in VN 
responsible for the negative feedback is 45R↓ in the 45RGD-motif even if other functionally 



































6.1.6 Development of an immunoassay for the detection of N-terminal VN fragments 
 
Proteolytic cleavage of matrix bound VN in the RGD-motif is expected to result in the 
release of an N-terminal VN-fragment (i.e. the SMB domain) from the connecting region 
and C-terminal hemopexin-like domains, which mediate the binding of VN to ECM 
components87, 89. To generate antibodies recognizing the N-terminal SMB domain of VN, 
we immunized VN-/- mice with a chimera protein containing the N-terminal region of 
human VN (residues 1-66) fused to the Fc region of a human IgG1 (VN(1-66)-Fc ). We 
obtained three antibodies (namely HU3, HF6 and IO35) reactive with the antigen, but non-
reactive with human IgG1 (data not shown). To map the binding epitopes, we used VN(1-
66)-Fc variants containing selected amino acid substitutions (Fig. 22).  
	  
Figure 22: Mapping of the binding epitopes of HF6, HU3 and IO35. 
96-well plates were coated with HF6 (A), HU3 (B) or IO35 (C), and incubated with VN(1-66)-Fc (100 
ng/mL) carrying different amino acid substitutions as indicated. The 54-66AG is a substitution of the 
residues 54-66 with a stretch of alternating alanine and glycine residues. Bound VN(1-66)-Fc was detected 
using an Eu3+-labeled secondary antibody directed against the human Fc moiety. Data are reported as 
percentage of the VN(1-66)-Fc WT, means ± SD of a representative experiment are shown. 
 
This analysis showed that HU3 binds to an epitope (called Bin A) in VN comprising 
residues Phe13 and Asp22 as alanine substitution of any of these two residues strongly 
reduced binding. Residues Phe13 and Asp22 of VN are well-described to be involved in 
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described antibody mAb153180. In contrast, HF6 binds to a second epitope (called Bin B) 
comprising residues Ala37 and Glu38. To our knowledge, antibodies against this epitope 
have not been described previously. Alanine substitution of Phe13 or Asp22 did not impair 
binding of HF6 and substitution of Ala37 (to glycine) or Glu38 did not impair binding of 
HU3 suggesting that the two epitopes are different and potentially non-overlapping. A 
third antibody, IO35, was found to bind downstream of the SMB-domain with a critical 
epitope (called Bin C) involving one or more residues in the VN(54-66) region, as the 
substitution of this region with a stretch of alternating Ala/Gly-residues prevents binding 
of the antibody. A cartoon of the binding epitopes is shown in Fig. 23.  	  
Figure 23: Cartoon illustrating the binding epitopes 
for HU3, HF6 and IO35 in VN. 
HU3 and HF6 bind to two different epitopes within the 
SMB domain, critical residues for the binding are F13 and 
D22 for HU3 (Bin A) and A37 and E38 for HF6 (Bin B). 
uPAR and PAI-1 share the same binding site of HU3. 
IO35 binds downstream the SMB domain and the RGD 
motif with critical residues in the region 54-66 of VN 
(Bin C). 
 
To test whether combinations of these antibodies could be used in a sandwich assay to 
measure SMB-containing VN fragments, we tested the ability of the different antibody 
pairs to contemporarily bind short un-tagged VN-fragments (Fig. 24). As predicted from 
the epitope mapping, pairs of antibodies belonging to different epitope bins were indeed 
able to detect short un-tagged VN-fragments demonstrating that the different epitope bins 
represent non-overlapping binding sites.  
The combination of HU3 for coating and biotinylated HF6 for detection was chosen for 















comparable detection of short and longer VN-fragments. The combination of HU3 as 
coating antibody and IO35 as detection antibody displayed a marked specificity towards 
longer fragments, consistent with the IO35 epitope being located in the region 54-66. It can 
therefore be used to discriminate between short N-terminal VN fragments (generated upon 
cleavage at 45R↓GD) and longer fragments or the full length protein. 
	  
Figure 24: Recognition of short N-terminal VN fragments by HF6, HU3 and IO35. 
Plates coated with HU3 (A) and HF6 (B) were incubated with conditioned medium of CHO cells expressing 
VN(1-45) (light grey columns) or VN(1-66) (dark grey columns) and the bound material was detected using 
biotinylated HF6, HU3 and IO35 as indicated. Means ± SD of a representative experiment are shown. 
 
6.1.7 uPAR-expressing cells accelerate the cleavage of matrix VN by uPA and Pli 
 
To investigate the occurrence of N-terminal VN fragments release, we treated VN 
immobilized on plastic with different forms of uPA and Plg in the absence or presence of 
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25). In the absence of cells only the treatment with Pli was found to release VN-fragments, 
consistent with the pre-treatment experiments (Fig. 13) whereas the presence of 293/uPAR 
cells resulted in a highly significant release of VN-fragments also by tc-uPA and the 
combination of sc-uPA, Plg and α2AP.  
	  
Figure 25: Plasminogen activation results in the release of N-terminal VN-fragments containing the 
SMB-domain. 
293/uPAR cells were seeded on VN and treated as indicated for 2 h at 37˚C. The supernatants were harvested 
and the level of SMB-containing VN-fragments was measured by HU3/HF6 immunoassay (see material and 
methods). Values represent the mean ± SEM of at least 3 independent experiments. The statistical 
significance was probed using Student’s t-test.  
 
To exclude that tc-uPA mediated release could be due to trace amount of Pli, we used the 
Pli inhibitor aprotinin that does not have any activity towards uPA (Fig. 26). Indeed, 
aprotinin treatment did not have any effect on release by tc-uPA while was highly 





























Figure 26: tc-uPA mediated release is not due to trace amount of Pli in the preparation. 
293/uPAR cells were plated on VN and treated with tc-uPA or with a combination of sc-uPA and Plg in the 
presence or absence of Pli inhibitors (α2AP and aprotinin). Supernatants were analyzed as described in the 
legend to Fig. 25. Values represent the mean ± SEM of 3 independent experiments. The statistical 
significance was probed using Student’s t-test.   
 
Furthermore, tc-uPA mediated release requires: (i) uPAR expression, as mock transfected 
cells did not induce release (Fig. 27A); (ii) uPA binding to uPAR, as the release was 
impaired by the GFD domain of uPA; (iii) uPAR binding to VN, as cells expressing a VN-
binding deficient uPAR mutant (uPARR91A) failed to promote the release and because an 
antibody blocking the interaction with VN (mAb 8B12, see material section) also 
prevented release (the mode of action of the different compounds/mutations utilized is 
depicted in Fig 28). Similar results were observed for the treatment with sc-uPA, Plg and 
α2AP (Fig. 27B), even if the inhibition by GFD and the impairment by the uPAR 91R→A 
































































Figure 27: The generation of soluble VN-
fragments containing the SMB-domain 
requires binding of both uPA and VN to 
uPAR. 
Cells were plated on VN and treated with tc-
uPA (A) or with a combination of sc-uPA, Plg 
and α2AP (B). Where indicated, 30 minutes 
pre-incubation with GFD or 8B12 was 
performed. Conditioned media were analyzed 
as described in Fig. 25. Values represent the 
mean ± SEM of 3 independent experiments. 
The statistical significance was probed using 
Student’s t-test.   
 
 
Figure 28: Cartoon illustrating the mechanism of 
action of the different compounds/mutations used in 
Fig. 27 
The monoclonal antibody 8B12 is a competitive 
inhibitor of the interaction between uPAR and VN. The 
Arg91 residue in uPAR is part of the VN-binding 
epitope of the receptor. The GFD domain of uPA is a 
competitive antagonist of uPA-binding to uPAR. 
 
These data show that VN-fragments containing the SMB-domain are released from VN 
containing matrices upon plasminogen activation in a highly specific process that requires 
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6.1.8 Binding of VN to uPAR accelerates cleavage by uPA  
 
The above data suggest that uPAR directly “catalyzes” the cleavage of VN through a 
mechanism of substrate presentation in which the receptor coordinates the enzyme (uPA) 
and its substrate (VN) favouring the contact between the catalytic triad in uPA and the 
RGD-motif in VN. If true, this model predicts that uPAR catalyzes VN-cleavage even in 
the absence of cells. To test this hypothesis, we incubated VN-coated wells with a fixed 
concentration of uPA together with increasing concentrations of an Fc-tagged soluble 
uPAR and measured the concomitant release of VN-fragments (Fig. 29A). Consistent with 
the hypothesis, the addition of soluble uPAR indeed resulted in a dose dependent release of 
SMB-containing VN-fragments. The release requires catalytically active tc-uPA as no 
release was observed with sc-uPA and requires binding of uPAR to VN as no significant 
release was induced by a VN-binding deficient variant of uPAR (uPARW32/R91A-Fc).  
	  
Figure 29: uPAR accelerate the generation of SMB-containing VN-fragments by uPA. 
 (A) Immobilized VN was incubated with 10 nM sc-uPA or tc-uPA together with a concentration curve of a 
soluble Fc-tagged uPAR (uPARWT) or a mutant form specifically deficient in VN-binding (uPARW32A/R91A). 
After 1 h of incubation, the supernatants were collected and analyzed for the presence of N-terminal VN-
fragments by HU3/HF6 immunoassay. The release is reported as percentage of the maximal signal observed 
in the experiment (10 nM uPARWT + tc-uPA). (B) After the recovery of supernatants for VN-fragment 
quantification, wells were washed and probed for bound uPAR-Fc using an Eu3+-labeled anti-Fc antibody. 
The specific binding is reported as percentage of the maximal binding observed in the experiment (10 nM 
uPARWT + sc-uPA). Data points represent the mean ± SEM of three independent experiments.  
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The levels of uPAR binding to VN (Fig. 29B) and the amounts of released SMB were 
directly proportional (Pearson r = 0.94, p < 0.0001, Fig. 30). 
	  
Figure 30: Levels of uPAR binding to VN and the release of VN fragments are strongly correlated. 
All the individual data points recorded in three experiments shown in Fig. 29A and B were analyzed by 
plotting uPAR-binding to VN versus SMB release. Pearson correlations are shown.  
 
To test whether these results could be an artefact of the forced uPAR dimerization caused 
by the presence of the Fc-tag, we repeated the same experiments comparing Fc-tagged 
soluble uPAR and un-tagged monomeric soluble uPAR (Fig. 31A and 31B). The presence 
of monomeric uPAR resulted in a dose dependent release of VN fragments but with lower 
efficiency compared to the Fc-tagged uPAR (Fig. 31A). This was paralleled by a less 
efficient VN binding of the monomeric uPAR compared to the Fc-tagged (Fig.31B). The 
correlation analysis between uPAR binding to VN and VN fragments release (Fig. 32) 
shows that comparable levels of binding to VN correspond to comparable release of VN 
fragments between monomeric and dimeric uPAR, further corroborating the concept that a 
key aspect for uPAR-mediated “catalysis” is its ability to bind VN. The release of VN 
fragments was not inhibited by an excess of aprotinin, thus excluding the presence of Pli 
contaminations in the different soluble uPAR preparations. 
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Figure 31: Monomeric soluble uPAR induces tc-uPA mediated cleavage of VN. 
(A) Experiments were conducted as described for Fig. 29, using a fix concentration of tc-uPA (10 nM) and 
comparing soluble uPAR-Fc and soluble untagged uPAR, in the presence or absence of 300 nM aprotinin. 
(B) uPAR binding to VN was quantified by incubation with R2 antibody followed by incubation with Eu3+-
labeled anti-mouse Fc antibody. Data points represent the mean ± SEM of three independent experiments. 
 
	  
Figure 32: The VN-binding capability of uPAR determines the extent of cleavage acceleration. 
All the individual data points recorded in three experiments shown in Fig. 31A and B were analyzed by 
plotting uPAR-binding to VN versus SMB release. Pearson correlations are shown.  
 
To obtain a quantitative estimation of the extent of cleavage acceleration mediated by 
uPAR, we incubated VN-coated wells with tc-uPA in the presence of uPAR-Fc or with 100 
times more tc-uPA in the absence of uPAR-Fc. Supernatants were collected at different 
time-points and analyzed for the presence of SMB-containing VN fragments (Fig. 33). The 
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release curves clearly show that the presence of uPAR results in higher cleavage 
acceleration compared to a 100-fold increase in the protease concentration. By linear 
regression of the initial part of the curves and slopes calculation, we estimated that the 
presence of uPAR results in a 300-fold increase in tc-uPA mediated cleavage of VN. 
	  
Figure 33: uPAR increases more than 100-fold the cleavage of VN mediated by tc-uPA. 
VN immobilized in 96-well plates was incubated with 3 nM tc-uPA in the presence of 10 nM soluble Fc-
tagged uPAR or with 300 nM tc-uPA alone. Supernatants were recovered at given time-points and analyzed 
for the presence of N-terminal VN-fragments by HU3/HF6 immunoassay. Dots represent the means ± SD of 
a representative experiment. Fitting of the initial part of the curves and slopes determination were done by 
linear regression using the GraphPad Prism (V6.0b) software. Estimation of the enzyme turnover rate was 
calculated dividing the slopes over the enzyme concentrations. 
 
To confirm these data by an independent method and to conclusively identify the cleavage 
site(s) for uPA in VN, MALDI-TOF analysis was conducted on VN incubated with tc-uPA 
in the presence or absence of uPAR. Both in the absence (Fig. 34A) and in the presence of 
the receptor (Fig. 34B), a molecular species corresponding to VN(1-45) was observed, but 
the intensity of this peak was consistently and significantly higher in reactions containing 
also uPAR (Fig. 35). 
 
 

























Figure 34: uPAR catalyzes uPA-mediated cleavage of the 45RG peptide bond – MALDI spectra. 
VN was subjected to tc-uPA digestion in the presence (B) or absence (A) of uPAR-Fc. Reactions were 
analyzed by MALDI-TOF mass spectrometry. Representative spectra are shown. 
 
	  
Figure 35: uPAR catalyzes uPA-mediated cleavage of 45RG peptide bond in VN – peak intensity. 
The experiment described in Fig. 34 was repeated 4 times and the intensity of 5160 Da peak was recorded. 
The graph shows the average relative intensity ± SEM of the 5160 Da peak from the 4 independent 
experiments, where the intensity of the 5160 Da peak of the tc-uPA alone condition of each experiment was 
set equal to 1. The statistical significance was probed using paired Student’s t-test.  
VN + tc-uPA
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These data thus demonstrate that uPAR accelerates uPA-catalyzed VN-cleavage and that 
the predominant cleavage position is 45R↓G consistently with the functional data. 
 
6.1.9 SMB-containing VN fragments are released by cancer cell lines 
 
We have shown that plasminogen activation results in the generation and release of N-
terminal VN fragments. To test if it occurs also in non over-expressing conditions, we 
exploited the NCI-60 panel, which is a collection of 60 human cancer cell lines belonging 
to 9 different cancer types (breast, central nervous system CNS, renal, ovarian, prostate, 
colorectal, lung, melanoma and leukemia). All the cell lines were tested for the ability to 
generate VN fragments when seeded on immobilized VN in the presence or absence of 
exogenously added Plg and α2AP (Fig.36). In the absence of Plg, very low levels of SMB 
release were scored with the exception of a leukemic cell line (HL60) (Fig.36A). On the 
contrary, Plg addition resulted in a significant increase of fragments release in all tumour 
types, except for leukemia cell lines (Fig.36B). The data thus indicate that cell lines 
expressing patho-physiological levels of uPAR are indeed capable to release N-terminal 
VN fragments and that this capability is not restricted to few cancer types. Notably, the 
extent of VN fragments release displays a marked variability among the different cell lines 





Figure 36: VN fragments are released by cancer cell lines. 
All the NCI-60 cell-lines were seeded on VN and treated with Plg + α2AP (B) or vehicle (A). The 
supernatants were harvested after 16 h and the level of SMB-containing VN-fragments was measured by 
HU3/HF6 immunoassay. Values represent the mean ± SD.  
 
To determine in an unbiased way what are the key cellular characteristics (i.e. genes) 
responsible for the release, we submitted the concentrations of VN fragments release in the 
absence or presence of Plg and α2AP as “patterns” to the CellMiner web tool181. This is an 
open-access bioinformatics tool that allows for pattern comparison between an input 
pattern of interest (i.e. VN fragments concentration) and gene expression across the NCI-
60 panel. The outputs of the analysis are all the possible correlations between the input 
pattern and the expression levels of about 26.000 genes. When submitting the pattern 
coming from no-treated cells, 881 genes were found to positively correlate (p<0.05) and 
387 to be negatively correlated with the levels of released VN fragments. The top one (r = 
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gene was also positively correlated (r = 0.32, rank = 440), indicating a possible direct 
involvement of the two endogenously expressed proteases in the cleavage of VN. The 
genes encoding for uPA (PLAU) and uPAR (PLAUR) were not found among the 
significant correlations. On the other hand, the analysis of the pattern of VN fragments 
release measured for Plg-treated cells resulted in the identification of 1033 positively and 
1258 negatively correlated genes. A first preliminary data analysis did not reveal any 
obvious connection between the top 10 genes and the studied biological process. 
Importantly, however, PLAU was found to be positively correlated  (r = 0.402, rank = 59). 
Of note, when restricting the analysis to the cancer cell lines of epithelial origin (n = 38), 
PLAU ranked number two with a strong and highly significant correlation (Fig. 37A), 
indicating, at least for epithelial cells, a strong connection between the expression of uPA 
and the ability of cancer cells to cleave VN. On the contrary, PLAUR still displayed no 
significant correlation (Fig. 37B).   	  
 
Figure 37: uPA expression but not uPAR correlates 
with the released SMB levels. 
Correlation analysis between PLAU (A) and PLAUR 
(B) mRNA expression levels with released SMB 
levels (Fig. 36B). The analyzed variables are 
expressed as Z-score that is a mathematical 
transformation used by CellMiner to centre and 























































6.1.10 N-terminal VN fragments are detectable in human urines 
 
Because of the small size of the VN-fragments generated by proteolytic cleavage by uPA 
and Pli, it is reasonable to think that if these are generated in vivo they are most likely 
filtered rapidly to the urinary compartment where they should be detectable. 
To test this hypothesis, we analyzed human urines samples from healthy volunteers with 
the HU3/HF6 immunoassay. All samples analyzed (n = 7) were positive for the presence of 
VN fragments (data not shown). However, a clear limitation of the assay is the lack of 
specificity as it can recognize SMB-containing VN fragments as well as the full-length 
protein. To discriminate between short and long VN fragments, we exploited the different 
specificity of the HU3/IO35 immunoassay, which does not detect short VN fragments 
generated upon cleavage at Arg45 (see Fig. 24). We calculated the ratio between the 
concentrations obtained with the two different assays (i.e. HU3/IO35 concentration divided 
by the HU3/HF6 concentration). When reported in percentage, a ratio of 100 means that 
the sample contains fragments that are longer than 1-66, on the contrary a ratio close to 0 
indicates the presence of shorter fragments. Consistently, when conditioned medium of 
CHO cells expressing VN(1-45) was analyzed, it resulted in a ratio equal to 6.5%, while 
conditioned medium of CHO cells expressing VN(1-66) displayed a ratio of 92% (Fig. 38). 
The same analysis conducted on urine samples showed that they mainly contain short VN-
fragments as evidenced by a ratio close to zero (average = 10.5%, Fig. 38). As control, we 
also analyzed a serum sample and we obtained a ratio of about 100, consistent with the 
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Figure 38: Human urines contain short N-terminal VN 
fragments. 
Indicated samples were analyzed by HU3/IO35 and HU3/HF6 
immunoassays. The HU3/IO35 extrapolated concentrations 
were divided over the concentrations calculated using 
HU3/HF6 measurements. Results are shown as percentage: a 
ratio of 100 (meaning equal recognition by the two assays) is 
indicative of samples containing long N-terminal VN 
fragments (≥1-66) while a ratio close to zero means that the 
sample contains shorter VN fragments. 
 
 
To identify the molecular species present in human urines, urine samples from healthy 
volunteers were immunoprecipitated with the HF6 antibody and the adsorbed material 
analyzed by MALDI-TOF. A representative spectrum is shown in Fig. 39. Three molecular 
species could readily be assigned to N-terminal VN-fragments: VN(1-41) (theoretical m/z 
= 4676.11), VN(1-42) (theoretical m/z = 4804.24), VN(1-44) (theoretical m/z = 5004.48). 
The N-terminal VN-fragments observed in urine are presumably generated from longer 
precursor fragments (possibly VN(1-45)) by progressive removal of C-terminal residues by 








































Figure 39: Three different molecular species of VN fragments are present in human urines. 
Human urine samples were immunoprecipitated with HF6-conjugated beads and the eluted material was 
analyzed by MALDI-TOF mass spectrometry. A representative spectrum (MW range = 2-20 kDa) and a 
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6.2 OPTIMIZATION AND VALIDATION OF THE HU3/HF6 IMMUNOASSAY FOR 
USE AS A CLINICAL GRADE ASSAY FOR THE DETECTION AND 
QUANTIFICATION OF URINARY N-TERMINAL VN-FRAGMENTS 
 
We have recently shown that the interaction between uPAR and VN plays an important 
role in cancer progression182. Since the generation of VN-fragments in vitro requires this 
molecular interaction and VN fragments are indeed release by cancer cell lines in vitro and 
detectable in human urines, it is tempting to speculate that the levels of VN-fragments in 
urine might represent a novel biomarker in cancer patients, as a surrogate for the activity of 
the plasminogen activation system in tumour tissues. 
To explore this possibility, we first needed to perform an exhaustive validation of the 
HU3/HF6 immunoassay to test its reliability and robustness. 
 
6.2.1 Dynamic range and assay precision 
 
To determine the dynamic range of the assay, a dilution curve of the reference protein 
(VN(1-61)) was prepared in assay buffer and the signal dose-response recorded (Fig. 40). 
The lower detection limit, defined as the concentration of VN(1-61) yielding a signal 
above background + 3 SD was found to be 3.3 fM. Similar, the upper detection limit 
defined by the concentration of VN(1-61) yielding a signal equal to saturation levels – 3 
SD was found to be 33 pM. The assay thus has a dynamic range of approximately four 
orders of magnitude. 
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Figure 40: Dynamic range of the HU3/HF6 immunoassay. 
Plates were coated with HU3 and incubated with a dilution curve of purified VN(1-61). Bound VN(1-61) 
was detected by subsequent incubations with biotin labeled HF6 and Eu3+-conjugated streptavidin. The 
binding curve was fitted to the experimental data by non-linear regression fit as described in Material and 
methods. The dynamic range of the assay is given by the detection limit and the saturation limit and is 
indicated by stippled vertical lines. The lower detection limit was calculated as the concentration of VN(1-
61) yielding a signal above background + 3 SD. The upper detection limit was calculated as the concentration 
of VN(1-61) yielding a signal equal to the saturation level – 3 SD. Grey zones indicate the average signal and 
noise +/- 3 times the SD recorded for the 16 negative and 16 positive control samples described in Fig. 41. 
 
The quality of an assay depends on both the S/N ratio as well as the data variability and the 
latter may be quantified using the Z-factor183. To determine the Z-factor for the HU3/HF6 
immunoassay, we measured the signal for 16 replicates of a negative control (assay buffer 
only) and 16 replicates of a positive control (10 nM VN(1-61) in assay buffer) and 
computed the Z-factor according to the formula: Z-factor = ((mean of positive controls – 3 
x SD) – (mean of negative controls + 3 x SD))/(mean of positive controls – mean of 
negative controls). The resulting S/N-ratio was 59 and the Z-factor 0.9, representing an 
excellent assay (Fig. 41). 
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Figure 41: S/N ratio and Z-factor of the assay. 
16 independent negative control samples (assay buffer alone, “Noise”) and 16 independent positive control 
samples (sample buffer containing 10 nM VN(1-61), “Signal”) were analyzed and the S/N-ratio and Z-factor 
calculated. The S/N-ratio was calculated as the mean signal of positive controls divided by the mean signal 
of the negative controls. The Z-factor was calculated as: ((mean positive controls – 3xSD) – (mean of 
negative controls + 3xSD)) divided by (mean positive controls – mean of negative controls). Grey zones 
indicate the average signal and noise +/- 3xSD recorded for the 16 negative and 16 positive control samples. 
 
6.2.2 Linearity of the assay 
 
To assess the optimal dilution of urine to use in the assay, a range of dilutions of the four 
different calibrator samples was made and assayed (Fig. 42). Compared to a reference 
dilution (1:1.600), the assay was found to be linear (+/- 20%) for sample dilutions in the 
range from 1:400 to 1:12.800 for all four calibrator samples. A urine sample dilution of 
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Figure 42: Assay linearity. 
Dilution curves of four calibrator samples (high, medium, low and matrice) were prepared in assay buffer 
and the apparent (“Measured”) concentration of VN-antigen quantified by extrapolation from a standard 
curve of VN(1-61). The actual (“Calculated”) concentration of VN-antigen in the samples was obtained by 
first setting the measured concentration at 1:1.600-fold dilution to 100% and then deriving the concentration 
at other dilutions by numerical correction for the different dilutions. The grey zone indicates 100 +/- 20% 
linearity. The vertical stippled lines indicate the dilution range for which all four calibrators display a linear 
response +/- 20%.  
 
6.2.3 Assay recovery 
 
To determine the recovery of the assay, the four calibrator samples were spiked with a 
curve of VN(1-61) and the apparent analyte concentrations measured and compared to the 
same spike-in curve prepared in assay buffer (Fig. 43). The spike in with VN(1-61) 
resulted in linear response curves with similar slopes to the curve observed for the spike in 
curve prepared in assay buffer demonstrating a complete recovery of analyte. The data 
demonstrate that urine at the analyzed dilution does not contain components that interfere 
with the accurate detection and quantification of N-terminal VN-fragments. 
























	   89	  
	  
Figure 43: Assay recovery. 
Assay buffer and the four calibrators (diluted 1:1.000) were spiked with a curve of VN(1-61) and the 
apparent concentration of VN-antigen measured. The slope of the curves is indicated in % of the slope 
calculated for VN(1-61) diluted in assay buffer. 
 
6.2.4 Assay variability 
 
To determine the assay variability within a single experiment (intra-assay variability) and 
between independent experiments (inter-assay variability) the four calibrators were 
measured 8 independent times in a single assay and in 9 independent assays (Fig. 44). The 
intra-assay variability (coefficient of variation) for the four calibrators was on average 
3.5% (range: 2.9-4.3%) and the inter-assay variability 10% (range: 8.3-12%). 


































Figure 44: Intra- and inter-assay variability. 
8 independent dilutions (1:1.000) of the four calibrators were measured in the same assay (same day, same 
plate) to determine the intra-assay variability, depicted with black dots. To measure the inter-assay 
variability, dilutions of the four calibrators were measured in 9 independent assays (different days), depicted 
with white dots. The calculated coefficients of variation (CV) are shown. 
 
6.2.5 Assay robustness 
 
To investigate the assay robustness in terms of sample storage temperature and freeze/thaw 
cycles, duplicate aliquots of the four calibrators were stored for three days at 4˚C, 25˚C and 
37˚C or subjected to six complete freeze/thaw cycles on consecutive days. The different 
samples were then measured in a single assay and the recorded values compared to those 
obtained for the same samples stored at -80˚C until the assay (Fig. 45). The storage at 
different temperature or multiple freeze/thaw cycles did not result in any reduction of 
measured concentration demonstrating that the analyte is very stable. The different 
treatments did result in an increased variability (average 11%, range 9.5-12%) not 
explainable by ordinary intra-assay variability (3.5%, see Fig. 44) suggesting that a 
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Figure 45: Assay robustness. 
Aliquots (n = 2) of the four calibrators were measured after storage for 3 days at the indicated temperatures 
or after 6 complete freeze/thaw cycles. The CV for the different calibrators is shown.  
 
6.2.6 Circadian variability 
 
An important property of a good biomarker is that it should be relatively stable at base line 
so that altered levels may be correlated with pathological processes such as disease and 
possibly also treatment efficacy. To address the long term stability of urinary levels of VN-
fragments, we measured the levels in consecutive early morning urine samples collected 
daily for a period of one month in one healthy male individual and one healthy female 
individual (Fig. 46A). The CV over one month for both individuals was 46%, however, 
after normalization for urinary creatinine levels (Fig. 46B) this variability was reduced 3-


























































Figure 46: Long-term variations in urinary VN-antigen levels. 
Early morning urine samples were collected every day for a month by two healthy volunteers (one male and 
one female) and the levels of VN-antigen measured. Graphs show measured VN fragments concentrations 
(A) and measured concentrations normalized on urinary creatinine levels (B) over time. Average levels are 
depicted by horizontal lines. The CVs are shown. 
 
The variability within a single day was measured in 3 healthy males and 4 healthy females 
and was found to be 64% before normalization (Fig. 47A) and about 3-fold lower (20%) 
after creatinine normalization (Fig. 47B).  
	  
Figure 47: Short-term variations in urinary VN-antigen levels. 
To determine the short-term variability in urinary SMB levels, three healthy male (M2, M3 and M5) and four 
healthy female (F1, F2, F3 and F4) volunteers collected urine samples every second hour from 8AM to 
10PM. In panel A, the measured levels of VN-antigen are presented in function of the sampling hour. 
Creatinine normalized values are shown in panel B. The CVs are shown. 
 
As the monthly variability is lower than the daily variability, these results show that the 
best accuracy is achieved by collecting the urine sample at the same time (i.e. early 
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morning urine) and normalizing for creatinine levels. The data furthermore confirm that 
urinary VN-fragments can be reliably measured and represent a stable biomarker. 
 
6.3 uPA·PAI-1 IS A SUPER-AGONIST OF THE uPAR-VN INTERACTION 
  
6.3.1 The uPA·PAI-1 complex is a super-agonist of the uPAR mediated cell adhesion to VN 
 
We have shown that the plasminogen activation cascade exerts regulative feedback loops 
on uPAR mediated cell adhesion on VN. A prediction of these findings is that specific 
inhibitors of the proteolytic activity of uPA and Pli may functionally act to enhance and 
stabilize cell adhesion in conditions where the plasminogen activation system is active. In 
this context, PAI-1 has peculiar characteristics. Indeed, complex formation between uPA 
and PAI-1 results in the loss of two activities that normally suppress cell adhesion i.e. 
competitive binding of PAI-1 to VN and proteolytic degradation of uPAR and VN by uPA 
and Pli, while the pro-adhesive effect of uPA is maintained. Therefore, we reason that the 
uPA·PAI-1 complex, in contrast to its molecular precursors, will be a stable and 
irreversible agonist of uPAR-mediated cell adhesion to VN. 
To address this hypothesis directly, we compared the individual and combined effect of 
uPA and PAI-1 on uPAR-mediated cell adhesion to VN (Fig. 48). As predicted from the 
competitive binding of uPAR and PAI-1 to the SMB of VN, the treatment with PAI-1 
caused a marked reduction in cell adhesion to VN mediated by uPAR. Similarly, the 
treatment with tc-uPA resulted inhibitory following the initial increase in cell adhesion. In 
contrast to the individual treatments, the combined treatment with tc-uPA and PAI-1 had a 
strong and persistent pro-adhesive effect. This result is fully consistent with our 
hypothesis, but the magnitude of the agonistic effect was unexpected. In fact, the treatment 
with a combination of tc-uPA and PAI-1, or purified uPA·PAI-1 complex, was clearly 
more agonistic than treatment with sc-uPA that represents a strong prototypic agonist. 
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Figure 48: uPA·PAI-1 complex is a super-agonist of uPAR-mediated cell adhesion to VN. 
RTCA analysis of 293/uPAR cells seeded on VN and treated at the indicated time-point. A representative 
experiment is shown. 
 
The “super-agonistic” effect of the complex resulted in a spread cell morphology (Fig. 49) 
even if the cell-matrix contact area (Fig. 50) did not increase as compared to treatment 
with the canonical agonist sc-uPA. Treatment with PAI-1 had the opposite effects causing 
evident rounding up of the cells and a reduced cell matrix contact area.  
	  
Figure 49: Morphology of 293/uPAR cells treated with different ligands. 
293/uPAR cells were seeded on VN-coated cover-slips, allowed to adhere and treated with different ligands 
for 1 h. The cells were fixed and DIC images recorded. Representative DIC images are shown. Scale bar, 10 
µM. 
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Figure 50: uPA·PAI-1 super-agonistic effect on uPAR-mediated adhesion to VN is not due to increased 
cell spreading. 
Cell-matrix contact area was quantified in the DIC images, collected in the experiment described in the 
legend to Fig. 49, using ImageJ. Twenty-five cells were quantified for each condition. Means ± SD of a 
representative experiment are shown. Statistical significance was probed using Student’s t-test. 
 
Of note, treatment with both PAI-1 and the uPA·PAI-1 complex inhibited cell migration 
(Fig. 51 and Movies 2 and 3). The cause of inhibition of migration was however clearly the 
opposite in support of the paradigm that both too strong (i.e. uPA·PAI-1 treated cells) and 
too weak (i.e. PAI-1 treated cells) cell adhesion preclude efficient cell migration. The 
block of cell migration by PAI-1 is transient, possibly because of inactivation of its VN 
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Figure 51: Effect of uPAR ligands on 2D cell migration on VN. 
293/uPAR cells were seeded in VN-coated wells and treated as indicated. Cells were imaged by time-lapse 
microscopy. Cell migration was quantified by manual tracking using the ImageJ software suite and the 
“manual tracking” plugin. The migration speed at a given time point was calculated as the average cell 
migration speed over the 30 minutes preceding the time point. The curves represent the average migration 
speed of 50 or more individual cells for each condition. The time at which cells were treated is depicted with 
a vertical dashed line. 
 
These data thus document that the uPA·PAI-1 complex is a stable agonist of the uPAR-
mediated cell adhesion to VN. Moreover, we here show for the first time that the complex 
is endowed with super-agonistic properties. 
 
6.3.2 PAI-1 counteracts the negative feedback and behaves as a proteolysis-dependent 
agonist of the uPAR-mediated cell adhesion on VN 
 
To investigate if the super-agonistic activity of the uPA·PAI-1 complex manifests itself in 
conditions where plasminogen activation is triggered, we conducted RTCA experiments 
with sequential additions of the proteases in their native zymogen forms as well as their 
inhibitors (Fig. 52). 293/uPAR cells were seeded on VN, allowed to adhere, and then 
treated with sc-uPA, PAI-1 or a mixture of the two. As predicted, the treatment with PAI-1 
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markedly reduced adhesion while sc-uPA was stimulatory. The cumulative effect of the 
pro-adhesive activity of sc-uPA and the anti-adhesive activity PAI-1 was a reduction in 
cell adhesion as compared to sham treated cells. To activate cell surface associated 
plasminogen activation, Plg and α2AP were added in a second step. Addition of Plg+α2AP 
to sc-uPA treated cells resulted in a steady decline in cell adhesion. In strong contrast the 
addition of Plg+α2AP to cells pre-treated with both sc-uPA and PAI-1 resulted in a sharp 
wave of cell adhesion. Addition of Plg+α2AP to sham or PAI-1 pre-treated cells had no 
effect (data not shown). 
	  
Figure 52: uPA generated during plasminogen activation stimulates cell adhesion to VN-coated 
matrices in the presence of PAI-1. 
RTCA analysis of 293/uPAR cells seeded on VN and treated as indicated. A representative experiment is 
shown. 
 
The data show that PAI-1 simultaneously blocks the negative feedback and enhances 































6.3.3 uPA·PAI-1 complex directly enhances uPAR-VN interaction 
 
It has been shown that the GFD domain of uPA is required and sufficient to induce the 
conformational change in uPAR that increases the receptor affinity for VN126. sc-uPA, tc-
uPA and the uPA·PAI-1 complex all contain this domain and display very similar binding 
affinity towards uPAR117. To understand if the super-agonistic activity of the uPA·PAI-1 
complex is mediated by an increase in the binding reaction between uPAR and VN or if 
other cellular processes are also involved, we compared the agonistic activity of sc-uPA, 
tc-uPA and uPA·PAI-1 in inducing uPAR-binding to immobilized VN using purified 
components (Fig. 53). Both sc-uPA and tc-uPA induced uPAR-binding to VN with similar 
EC50, but the Bmax was higher for sc-uPA presumably because of the uPAR and/or VN 
cleavage occurring during the binding reaction. Notably, the uPA·PAI-1 complex was 
clearly a stronger agonist displaying about three-fold lower EC50 and twice the Bmax as 
compared to sc-uPA.  
	  
Figure 53: The uPA·PAI-1 complex is a super-agonist of the interaction between uPAR and VN. 
96-well immunoplates were coated with VN and incubated with a fixed concentration of Fc-tagged uPAR 
(10 nM) in the presence of a dilution curve of sc-uPA, tc-uPA and uPA·PAI-1 complex as indicated. After 2 
h of binding, plates were washed and probed for bound uPAR-Fc using an Eu3+-labeled anti-Fc antibody. 
Dots represent the means ± SD of a representative experiment. Curves fitting and determination of EC50 and 
Bmax were done by non-linear regression using the log[agonist] vs. response – variable slope (four parameter) 
algorithm and the GraphPad Prism (V6.0b) software. 
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The strong agonistic activity of the uPA·PAI-1 complex is unlikely to be caused by 
increased uPAR-binding as it is, if anything, a weaker antagonist of the uPA/uPAR-
interaction (Fig. 54). It thus appears plausible that the strong pro-adhesive activity of the 
uPA·PAI-1 complex is caused by an increased stability of the PAI-1·uPA·uPAR·VN 
complex as compared to the sc-uPA·uPAR·VN complex. 
	  
Figure 54: uPA·PAI-1 super-agonistic activity is not due to higher affinity of the uPA·PAI-1 complex 
for uPAR. 
The same reaction mixtures used in Fig. 53 were also tested for uPAR-binding activity towards immobilized 
sc-uPA. This assay was conducted exactly as described for Fig. 53 with the only exception that plates had 
been coated with sc-uPA. Dots represent the means ± SD of a representative experiment. Curves fitting and 
determination of IC50 values were performed by non linear regression using the log[inhibitor] vs. response – 
Variable slope (four parameters) algorithm and the GraphPad Prism (V6.0b) software. 
 
6.3.4 Mechanism of the PAI-1·uPA·uPAR·VN complex formation 
 
As the interaction with VN stabilizes PAI-1 in an active conformation52, it is likely that the 
physiologically relevant inactivation of uPA by PAI-1 occurring in tissues may 
predominantly happen between uPAR-bound uPA and VN-bound PAI-1. To investigate if 
these conditions can be reconstituted using purified components, we analyzed the binding 



























of sc-uPA/tc-uPA-bound uPAR to immobilized VN saturated with PAI-1 (Fig. 55). 
Saturation of VN with PAI-1 completely blocked the subsequent binding of the sc-
uPA·uPAR-complex consistent with the fact that the binding of PAI-1 and uPAR to VN 
are mutually exclusive and that the affinity of PAI-1 for VN is higher that the affinity of 
uPAR for VN131. In contrast, uPAR in the presence of tc-uPA bound very efficiently to VN 
surfaces pre-saturated with PAI-1, consistent with the agonistic effect of the uPA·PAI-1 
complex. 
	  
Figure 55: Complex formation between uPA and PAI-1 is required to promote uPAR binding to VN. 
96-well immunoplates were coated with VN and saturated with PAI-1 or PAI-1R346A mutant and washed 
extensively. Wells were added a fixed concentration of uPAR-Fc mixed with a dilution curved of sc-uPA or 
tc-uPA as indicated. Bound uPAR-Fc was detected as described in the legend to Figure 53. Dots represent 
means ± SD of a representative experiment. 
 
The inactivation of uPA by PAI-1 involves major conformational changes in the inhibitor 
that results in a complete loss of binding activity towards VN184. The inhibition hereby 
causes the dissociation of PAI-1 from VN, liberating the SMB-domain and possibly 
allowing for the binding of uPAR. As only catalytically active tc-uPA reacts with PAI-1185, 
the difference in binding of uPAR to PAI-1 saturated VN induced by sc-uPA and tc-uPA 
may thus be accounted for PAI-1 dissociation induced only by tc-uPA. To address this 
hypothesis directly, we repeated the binding experiment using a PAI-1 variant carrying a 
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RCL mutation (PAI-1R346A) that prevents its interaction with tc-uPA48, but maintain normal 
binding to VN132. Consistent with the hypothesis, the pre-incubation of VN with PAI-
1R346A prevented the subsequent binding of uPAR loaded not only with sc-uPA, but also 
with tc-uPA (Fig. 55).  
Dissociation of PAI-1 from VN is required to liberate the binding site for uPAR. To test 
this in our in vitro setting, we repeated the experiments using an active site mutant uPA 
(tc-uPAS356A) that binds PAI-1, but fails to hydrolyze the RCL of PAI-1. As RCL cleavage 
is the event that triggers the conformational change in PAI-1, this mutant should therefore 
not dissociate PAI-1 from VN and consequently not liberate the binding site for uPAR. 
Nevertheless, the tc-uPAS356A mutant was a potent inducer of uPAR binding to VN coated 
surfaces incubated with PAI-1 (Fig. 56). This could be due to the existence of a quaternary 
complex intermediate, uPAR·uPA·PAI-1·VN, that transiently connects uPAR to VN even 
if the two molecules do not touch each other. The half-life of this quaternary complex is 
expected to be short, as the reaction of uPA with PAI-1 rapidly leads to the disassociation 
of the latter from VN. As tc-uPAS356A binds to PAI-1, but fails to induce its dissociation 
from VN, the linear quaternary complex (uPAR·uPAS356A·PAI-1·VN) may be stable and 







Figure 56: Pre-incubation of VN with PAI-1 increases subsequent uPAR binding induced by uPA and 
the catalytic activity of uPA is dispensable. 
VN-coated wells were saturated with PAI-1 or left untreated (no) and incubated with a fixed concentration of 
uPAR-Fc (10 nM) mixed with a dilution curve of tc-uPA or an uPA variant (tc-uPAS356A) which does bind 
PAI-1, but lacks catalytic activity. Binding of uPAR to VN was quantified as for Fig. 53. Dots represent 
means ± SD of a representative experiment.  
 
A hallmark difference between the linear (uPAR·uPA·PAI-1·VN) and the branched 
(VN·uPAR·uPA·PAI-1) quaternary complexes is the requirement for direct uPAR binding 
to VN. In fact only for the branched complex, this interaction should be important. To test 
this prediction, we conducted binding assays using a receptor mutant (uPARW32A/R91A) that 
displays a complete and specific deficiency in VN binding186. Consistent with the model, 
this mutant readily supported tc-uPAS356A induced uPAR binding to PAI-1 treated VN 
coated surfaces, but not VN binding induced by tc-uPAWT (Fig. 57).  
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Figure 57: The VN binding site is required for tc-uPA mediated uPAR binding and dispensable for tc-
uPAS356A induced binding. 
VN-coated wells were saturated with PAI-1 and incubated with a fixed concentration of uPAR-Fc or 
uPARW32A/R91A-Fc mixed with a dilution curve of tc-uPA or tc-uPAS356A as indicated. Binding of uPAR-Fc 
variants to VN was measured as for Fig. 53. Dots represent means ± SD of a representative experiment.  
 
Control experiments confirmed that the uPARW32A/R91A variant is indeed VN-binding 
deficient as no or little binding to VN was observed with this receptor variant (Fig. 58). As 
shown above, the VN-binding of uPARWT observed in the presence of the uPA·PAI-1 
complex the is superior to the binding observed in the presence of sc-uPA confirming the 
super-agonistic activity of the uPA·PAI-1 complex also in this assay. 


























Figure 58: The VN binding site in uPAR is required for both sc-uPA and uPA·PAI-1 induced VN 
binding. 
Constant concentrations of uPAR-Fc and uPARW32A/R91A-Fc were mixed with dilution curves of sc-uPA and 
uPA·PAI-1 complex and added to VN coated wells. uPAR binding to VN was measured as described for Fig. 
53. Dots represent means ± SD of a representative experiment.  
 
As we found that receptor binding to VN in the presence of uPA·PAI-1 is mediated almost 
exclusively by the VN binding site in uPAR, the model also predicts that the VN-binding 
site in PAI-1 should be dispensable. To verify this, we measured the binding of uPAR to 
VN in the presence of tc-uPA and a PAI-1 mutant (PAI-1R103A/M112A/Q125A) that displays 
normal reactivity with uPA, but completely fails to bind VN187. In these experiments (Fig. 
59), we found that PAI-1 and PAI-1R103A/M112A/Q125A are equally efficient in inducing uPAR 
binding to VN demonstrating that the main VN binding site in PAI-1, involving residues 
Arg103, Met112 and Gln125, does not contribute to the VN binding activity of the 
uPAR·uPA·PAI-1 complex.  
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Figure 59: The VN binding site in PAI-1 is dispensable for the super-agonistic activity of the uPA·PAI-
1 complex in inducing uPAR binding to VN. 
Constant concentrations of uPAR-Fc (10 nM) was mixed with a constant concentration of tc-uPA (5 nM) and 
a dilution curve of PAI-1 WT or mutant. The mixtures were added to VN coated wells and uPAR binding 
measured as described for Fig. 53. Dots represent means ± SD of a representative experiment.  
 
Taken together these data unequivocally demonstrate the mechanism outlined in Fig. 60, in 
which the complex formation by uPA and PAI-1 promotes uPAR binding to VN, through a 
series of discrete binding and dissociation reactions.  























Figure 60: Cartoon depicting the mechanism responsible for uPAR binding to VN mediated by 
complex formation between uPA and PAI-1. 
Active uPA (i.e. tc-uPA) bound to uPAR reacts with VN-bound PAI-1 to generate a linear quaternary 
complex (“indirect complex”). This complex formation (reaction A) requires interactions between uPA and 
PAI-1 as both sc-uPA and PAIR346A mutant fail to support binding (Fig. 55). The formation of this complex 
does not involve the catalytic activity of uPA (Fig. 56) or the VN binding site in uPAR (Fig. 57). As PAI-1 is 
released from VN when it reacts with uPA the linear quaternary is instable (reaction B), however, the 
dissociation is blocked by catalytically inactive uPA (tc-uPAS356A) (Fig. 57). Dissociation of the 
uPAR·uPA·PAI-1 from VN liberates the uPAR binding site in VN and is therefore followed by the 
generation of branched “direct complex” mediated by a direct interaction between uPAR and VN (Fig. 58). 
The VN binding site in PAI-1 is not involved for the generation of this complex (Fig. 59). 
 
Our data document the mechanism by which complex formation between uPA and PAI-1 
promotes uPAR binding to VN, however, they do not explain why the apparent affinity 
and capacity of uPAR binding to VN is higher when in complex with uPA·PAI-1 as 
compared to uPA. It is reasonable to assume that yet-to-be-described protein-protein 
interactions present in the quaternary VN·uPAR·uPA·PAI-1 complex, but absent in the 
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knowledge there are no well-documented interactions described in the literature and a 
systematic experimental approach will therefore be required to determine the structural 







Figure 61: Cartoon illustrating the molecular mechanism of the cross-talk between plasminogen 
activation and cell adhesion to VN. 
(A) Binding of sc-uPA to uPAR alters the conformation of the receptor increasing its affinity for VN. 
Binding of uPAR to VN in the ECM promotes cell adhesion and the contact between integrin receptors and 
the RGD-motif of VN. (B) uPAR-bound sc-uPA is prone to activation by other membrane associated serine 
proteases including Pli and once it becomes activated it will revert cell adhesion by proteolytic inactivation 
of the RGD-motif in VN as well as by cleavage of uPAR. (C) PAI-1 counteracts the negative feedback and 
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7. DISCUSSION 
 
7.1 NEGATIVE FEEDBACK BETWEEN uPAR INDUCED EXTRACELLULAR 
PROTEOLYSIS AND CELL ADHESION TO VN 
 
We here report that the proteolytic activities of uPA and Pli exert a major negative 
feedback on integrin- and uPAR-mediated cell adhesion on VN. We show that uPA and Pli 
inactivate the adhesive activities of VN predominantly through cleavage of the 45R↓G 
peptide bond in the N-terminal region of the molecule. Proteolysis at this position directly 
inactivates the 45RGD-motif responsible for integrin binding and results in the separation 
of the uPAR and PAI-1 binding determinants, located in the N-terminal SMB domain, 
from the connecting region and hemopexin-like repeats responsible for the tethering of VN 
to the ECM (Fig. 61B).  
 
7.1.1 uPAR cleavage 
 
As previously hypothesized158, the proteolytic feedback is partially mediated by uPA/Pli 
catalyzed proteolytic inactivation of uPAR, but this mechanism appears to be 
quantitatively less important than the direct cleavage of VN. The fact that the cleavage of 
the anchoring receptor (i.e. uPAR) responsible for the high adhesion of 293/uPAR cells to 
VN is of little importance is somehow unexpected. A possible explanation has been given 
by a recent study in which it has been shown, using surface plasmon resonance, that the 
complex between the D1 of uPAR and sc-uPA displays a high affinity binding to 
immobilized D2D3188. As a consequence, the cleavage of uPAR in the D1-D2 linker region 
may not result in a fast dissociation of D1, leaving a VN-binding competent receptor on 
the cell surface. 
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7.1.2 VN cleavage 
 
Pli has been previously shown to cleave VN at multiple locations in the central and C-
terminal regions of the protein11, 177 and cleavage in or close to the RGD-motif has been 
reported for other enzymes. The serine protease granzyme B, released by cytotoxic T-cells, 
has been shown to cleave VN immediately downstream of the RGD-motif (45RGD↓V)189 
and the cancer-related serine protease tissue kallikrein 14 has been shown to cleave within 
the RGD-motif (45R↓GDV)190 at the same location reported for uPA and Pli here. In 
addition, it has also been reported that members of the MMPs family cleave VN in more 
C-terminal regions191, 192. 
Treatment of VN with Pli has been shown to prevent subsequent αvβ5-mediated adhesion 
of the keratinocyte cell line HaCaT178, however if VN was actually cleaved, and where, 
was not addressed in the study. uPAR-dependent cell surface plasminogen activation has 
also been shown to cause the retraction of cultured human umbilical vein endothelial cell 
monolayers175, but whether this effect was mediated by cleavage of VN was not addressed. 
The evidence presented here clearly provides an appealing mechanism by which these 
observations may be explained at the molecular level. 
 
7.1.3 uPAR “catalyzes” the cleavage of VN mediated by uPA 
  
In contrast to Pli, uPA is endowed with very narrow substrate specificity. Only two 
substrates (i.e. Plg and uPAR) have been carefully characterized and, in addition, PAI-1 
may be considered as a peculiar uPA substrate. We here identify VN as a novel and the 
first described uPAR-dependent substrate for uPA. Indeed, the cleavage of VN by uPA is 
dependent upon uPAR both in vitro, using purified proteins, as well as in cell culture 
suggesting that uPAR catalyzes the cleavage reaction by a mechanism of substrate 
presentation in which the receptor coordinates the protease (uPA) and the substrate (VN) in 
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a ternary complex in which the hydrolysis reaction is greatly favoured. We have estimated 
that the presence of uPAR accelerates the cleavage of VN mediated by uPA more than 300 
times. However, the use of immobilized VN as substrate does not allow us to calculate 
kinetics parameters such as Km, Vmax and Kcat. To this end, a fluorophore/quencher 
approach may be employed, by preparation of short labelled recombinant VN variant (e.g. 
VN(1-61)).   
 
7.1.4 Cancer cells lines release SMB-containing fragments in vitro 
 
Using the NCI-60 panel of cancer cell lines, we have shown that VN fragments are 
released also by cells expressing patho-physiological uPAR levels.  
In the absence of exogenous Plg, only the human promyelocytic leukemic HL60 cells were 
capable of efficiently release N-terminal VN fragments. Remarkably, this cell line is the 
one in the panel that expresses the highest levels of neutrophil elastase and Plg, indicating 
a possible role of these proteases in the cleavage of VN. In contrast to Pli, no cleavage sites 
are known for neutrophil elastase in VN. However, it has been reported that neutrophil 
elastase can increase fibrinolysis through cleavage and inactivation of PAI-1193 as well as 
through the conversion of Glu-Plg to the more susceptible form Lys-Plg194. 
In the presence of Plg, the release of VN fragments is significantly increased in several 
cancer cell lines belonging to all the cancer types present in the panel, with the exception 
of leukemic cell lines. Remarkably, the levels of fragment release in the cancer cell lines 
with epithelial origin is highly correlated with PLAU expression levels, clearly identifying 
a strong connection between uPA expression and the ability of cells to cleave VN. Since 
uPA levels are a well-known marker of poor prognosis, this finding corroborates the idea 
that N-terminal VN fragments may have similar prognostic value, at least for epithelial 
cancers.  
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Despite the highly significant correlation between uPA expression levels and the extent of 
VN fragments release in epithelial cancer cell lines (rank = 2, r = 0.57, p < 0.0001, Fig. 
37A), the expression of uPAR gene is not significantly correlated with VN fragments 
release (r = 0.03, p = 0.85, Fig. 37B). This finding is clearly not in accordance neither with 
our experiments performed with uPAR-overexpressing cells and with purified proteins in 
vitro nor with fact that uPAR should be a central regulator of cell surface plasminogen 
activation. We currently have no explanation for this finding. One possibility is that uPA 
cell surface receptors different from uPAR are relatively more important. Another possible 
explanation is that the long Plg incubation performed in the experiments (16 h) has 
allowed free uPA to activate cell surface Plg, despite the low catalytic efficiency of uPA 
when present in solution-phase109.   
 
7.1.5 Implications and future perspectives 
 
It is widely believed that the function of uPAR in extracellular proteolysis is to accelerate 
plasminogen activation and to localize the activated proteases on the cell surface. The data 
presented here show that matrix VN is a substrate for these membrane-associated 
proteolytic enzymes. While Pli is crucial for fibrin surveillance in vivo113, the only process 
that has been well-documented to require the binding of uPA to uPAR in vivo is the 
suppression of inflammation secondary to fibrin deposition115. We propose that while Pli is 
responsible for the resolution of fibrin deposits in the provisional matrix subsequent to 
tissue injury, the primary function of uPAR/uPA may be to bind and promote the focused 
resolution also of the VN component present in these lesions.  
Experiments with cells expressing physiological levels of uPAR will give us more hints to 
hypothesize about the possible functional relevance of VN cleavage. On the one hand, we 
are currently exploiting the NCI-60 panel to perform a correlative analysis as already done 
for the SMB release. On the other hand, migration, chemotaxis and invasion experiments 
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using cancer cell lines, leukocytes or fibroblasts may also give important indications. 
However, the localization of the uPA and Pli cleavage site in VN represents a major issue 
to perform such structure-function experiments. Indeed, it is currently not possible to block 
the cleavage of VN (i.e. using the 45R→A mutation in VN) without also blocking integrin 
binding. As integrins are predominantly responsible for cell adhesion to VN, virtually all 
the cell lines will adhere poorly to VN variants carrying mutations in the RGD motif. The 
use of mixed coating (e.g. VN plus FN or collagen embedded with the different VN 
variants) may represent a possible solution to this problem and also provide a more 
physiological matrix compared to the single purified components. 
Finally, future studies with knock-in animals may shed light on the in vivo relevance of the 
VN cleavage. VN-/- mice are viable and fertile with no major phenotypes195, therefore the 
introduction of single amino acid substitution in the VN gene is not expected to result in 
severe phenotypes. However, VN-/- mice display detectable phenotypes when challenged 
with external insults. Indeed, the mice display impaired leukocytes recruitment at site of 
inflammation and ischemia196 and a slight delay in skin wounds closure197. Comparing 
knock-in animals, bearing the 45R→A and the 46G→A substitution or the intact RGD, may 
reveal a role of the cleavage of VN in these processes. We have recently shown that VN 
and specifically the uPAR-VN interaction plays an important role in tumour growth in 
vivo182; similar experiments with the VN mutants knock-in animals may contribute to 
further characterize the role of VN, and VN cleavage, in tumour progression and 
dissemination. 
 
7.3 SMB-CONTAINING FRAGMENTS ARE PRESENT IN VIVO 
 
We here show that SMB-containing N-terminal VN fragments are present in human urines. 
Three different species, corresponding to VN(1-41), VN(1-42) and VN(1-44) are readily 
detected and present at variable relative concentrations in all urine samples analyzed so far 
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(Fig. 39 and data not shown). Preliminary data on urines of cancer patients show no 
qualitative difference in the fragment pattern of cancer patients compared to healthy 
volunteers.  
These fragments may derive from longer precursors, such as VN(1-45), further trimmed by 
carboxypeptidases present in the blood circulation as well as in urines. In particular, a 
specific subgroup of carboxypeptidases, called carboxypeptidases B (basic), is composed 
of proteases that specifically cleave C-terminal basic residues (i.e. Lys and Arg). They 
could account for the absence of the VN(1-45) fragment, whose terminal Arg residue 
might be readily removed by such enzymes. The thrombin-activatable fibrinolytic inhibitor 
(TAFI) may represent an interesting candidate. Indeed, TAFI is a metallocarboxypeptidase 
that removes C-terminal basic residues. It is present in the blood stream and activated by 
thrombin in the coagulation cascade as well as by Pli in the fibrinolytic process198. 
The smallest fragment detected is VN(1-41). Remarkably, the residue 41 of VN is a Pro. 
Among the 21 amino acids, Pro is the only secondary amine and its peculiar structure 
makes peptide bonds with Pro as P1’ residue resistant to proteolysis. Specific prolyl 
carboxypeptidases remove C-terminal residues adjacent to a Pro, but they do not remove 
Pro residues. This may explain why we do not observe shorter fragments in urine samples. 
Similar N-terminal VN fragments have previously been described. Indeed, the SMB 
domain was discovered in the 1970’s as a circulating peptide in human plasma199, 200. The 
presence of additional N-terminal VN fragments in hemofiltrates of patients with end stage 
renal disease has also been reported201. In addition to VN(1-44), other three molecular 
species, i.e. VN(1-48), VN(1-49) and VN(1-50), have been described. We do not observe 
such fragments in our samples, even if their molecular weight (less than 5.7 kDa) would 
allow their filtration in the urinary compartment. This may suggest that the accumulation 
of those fragments in the circulation is peculiar of patients with kidney disease and 
therefore not present in the blood of healthy individuals or cancer patients. Alternatively, 
these fragments, even if present in the blood stream, may be further digested in the urines 
	   115	  
and therefore not detected in our MALDI spectra. Moreover, the absence of VN(1-41) and 
VN(1-42) fragments in the hemofiltrates201 may indicate that the removal of Gln42, Val43 
and Thr44 is specifically catalyzed by urinary carboxypeptidases. 
The presence of SMB-containing peptides in human urines has also been previously 
documented202. SMB immunoreactivity was observed in the urines of 8 adult healthy 
individuals. Notably, the 85.9% of the SMB present in urines is found in a “free” form, 
whereas the SMB present in the plasma of the same subjects is described as almost 
completely (more than 95%) “bound to serum proteins”. We know now that the SMB is 
the N-terminal domain of VN but, when this study was performed, VN had not been 
characterized yet. These findings are therefore consistent with our data (Fig. 38), which 
show that about the 90% of the SMB-containing antigen present in urine samples 
represents short N-terminal VN fragments, while in blood samples virtually 100% of the 
signal is given by longer fragments, presumably the full length VN.    
 
7.4 THE USE OF N-TERMINAL VN FRAGMENTS AS CANCER BIOMARKER 
 
High levels of uPAR and/or uPA/PAI-1 have been shown to have a strong prognostic value 
in several carcinomas, including breast, lung, colon and gastric cancers. In particular, uPA 
and PAI-1 levels in breast tumour tissues are, together with ERBB2-status, the only novel 
breast cancer biomarkers to be fully supported by the highest level of evidence (LOE-1) of 
clinical utility203, 204. Indeed, it has been shown that node negative breast cancer patients 
can be stratified using uPA/PAI-1 levels in tumour extracts: low levels indentify a low risk 
group having a very good prognosis, whereas patients with high levels of uPA/PAI-1 
display higher relapse risk and derive significant benefit from an adjuvant chemotherapy 
regimen. The use of uPA and PAI-1 has been included in the 2007 update of the American 
Society of Clinical Oncology recommendations for clinical decision-making in node-
negative breast cancer patients. Nevertheless, the use of these biomarkers is not 
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widespread mainly for the logistic limitation of requiring fresh-frozen specimens, which 
may be not available in all hospitals.  
We here propose the use of urinary N-terminal VN fragments as a novel cancer biomarker. 
The idea stems from previous work done in the lab in which we have shown that the 
interaction between uPAR and VN plays a pivotal role in tumour growth in vivo182. Since 
efficient VN cleavage requires this interaction, our hypothesis is that the levels of VN 
fragments in urine samples may represent a novel biomarker in cancer patients, as a 
surrogate for the activity of the plasminogen activation system in the tumour tissue. 
Potential uses may be prognosis (i.e. high levels of urinary VN fragments might correlate 
with a poor prognosis) and patient stratification. At present, despite all the evidences 
linking the uPA-system with cancer, no targeted therapy against components of the uPA-
system is available for cancer patients. uPAR inhibitors and specifically inhibitors of the 
uPAR-VN interaction have been developed in our lab and are currently undergoing 
extensive pre-clinical studies. In view of an anti-uPAR therapy, our immunoassay may 
represent a suitable tool for patient stratification, to select patients more likely to respond, 
as well as for non-invasive monitoring of the response to therapy.  
The nature of the specimen required (i.e. early morning urine) clearly facilitates the use of 
this biomarker compared to uPA/PAI-1. However, it also implies some limitations, for 
instance it can not be used for patients with kidney disease who suffer from proteinuria, as 
high levels of full length VN are likely to be present in the urines of such patients. 
Similarly, follow-up measurements of urinary VN fragments will not be possible in 
patients subjected to therapy associated with nephrotoxicity side-effects (e.g. some 
chemotherapeutics). In addition, enzymes such granzyme B189 and tissue kallikrein 14190 
have been reported to cleave VN in vitro close or within the RGD motif of the protein, thus 
potentially generating VN fragments similar to those generated by uPA and Pli. These 
fragments would be detected by our immunoassay and might therefore represent a signal 
not related to the uPA-system activity in the tumour tissue. Possibly, some of these issues 
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may be overcome by developing an immunoassay specific for the VN(1-44) fragments, 
which therefore would allow the analysis of blood samples. 
A small exploratory study on breast cancer patients’ urine samples is already planned. We 
will analyze urine samples of newly diagnosed primary breast cancer patients, with the 
objective of evaluating the basic parameters of urinary VN fragments. Correlation analyses 
between VN fragments urinary levels and standard clinical-pathological parameters (e.g. 
age, tumour size, number of lymph nodes involved and hormone receptor and ERBB2 
status) will be performed to evaluate the feasibility of larger future studies. 
 
7.5 VALIDATION OF THE HU3/HF6 IMMUNOASSAY 
 
Our immunoassay for the detection of SMB-containing VN fragments is based on a 
sandwich-type TR-FIA. Two monoclonal antibodies, with non-overlapping epitopes within 
the SMB domain of VN, are used for the capturing (HU3) and the detection (HF6) of the 
antigen. This design is clearly not specific for VN fragments and therefore prevents us 
from measuring such fragments in serum or plasma samples that are rich in VN. Hence, we 
focused on urine samples where the SMB antigen signal is mainly given by short N-
terminal fragments (shorter that 1-65, Fig. 38).  
A robust validation of the assay is a key aspect for a biomarker success. To this end, we 
have assessed a number of assay parameters to optimize the assay and evaluate its overall 
quality (Fig. 40-45). The assay exhibits a large dynamic range and linearity range and high 
sensitivity (detection limit in the femtomolar range). The precision (in term of CV) in 
repeated analyses of calibrator samples is expected to vary less than 25-30% in ELISA-
based measurements of macromolecules205. The variability, both intra- and inter-day, was 
found to be less than 5% and 15% respectively, thus indicating that our immunoassay is 
indeed highly reproducible and precise. Since an analyte-free matrix is non available (i.e. 
SMB depleted human urines), the standard curve is prepared in dilution buffer (i.e. PBS + 
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0.1% Tween). To specifically test whether the difference between the diluent and the 
sample matrix may affect the assay results, we performed spike-in experiments and found 
that the analyte recovery is virtually 100% in all four calibrators samples. Finally, we 
assessed the stability to storage and freezing/thawing cycles of the VN fragments in urine 
samples. Results show a high stability with little variability associated with the different 
storage conditions. Taken together, these data clearly indicate that the HU3/HF6 
immunoassay has very good performance characteristics and can be employed to reliably 
measure N-terminal VN fragments in human urine samples. Depletion and mass 
spectrometry experiments are still missing to complete the validation process. 
A key characteristic of a biomarker is the constancy under normal physiological 
conditions. Urinary levels of the VN fragments showed little fluctuations when normalized 
on the creatinine concentration, particularly when analyzing early morning urine samples. 
However, the analysis of healthy volunteers samples also showed quite high basal levels 
(around 50 nM) compared for instance with suPAR levels in urines, which are in the 
picomolar range206. As a consequence, detecting eventual increases due to pathological 
conditions might be problematic. 
 
7.6 THE uPA·PAI-1 COMPLEX IS A SUPER-AGONIST OF THE uPAR/VN 
INTERACTION 
 
We here report that PAI-1 counteracts the negative feedback mediated by uPA and Pli and 
behaves as a proteolysis-dependent super-agonist of the uPAR-VN interaction (Fig. 61C). 
Indeed, PAI-1, in the absence of active uPA, inhibits uPAR-mediated cell adhesion by 
competing for the binding to the SMB domain of VN. On the other hand, we have shown 
that the complex formation between tc-uPA and PAI-1 results in a potent agonistic effect 
on the uPAR-VN interaction and cell adhesion to VN, which is stronger than the effect 
mediated by sc-uPA. Using purified components in vitro, we have shown that this strong 
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induction does not involve proteins other than uPA, uPAR, PAI-1 and VN. We have 
characterized the mechanism of the uPA·PAI-1 complex formation and shown the 
existence of a quaternary intermediate uPAR·uPA·PAI-1·VN. However, at the moment, we 
do not know the structural basis of the increased affinity of uPAR for VN induced by the 
uPA·PAI-1 complex. Indeed, the uPA·PAI-1 complex induces uPAR binding to VN with a 
much lower EC50 compared to sc-uPA. Unexpectedly, the complex also displays a double 
Bmax compared to sc-uPA. The Bmax is a measure of the number of binding sites present in 
the well and therefore should be identical as the VN coating was not changed between the 
two conditions. This suggests that the difference between the two ligands may be due to an 
increased stability of the PAI-1·uPA·uPAR·VN complex compared to the sc-
uPA·uPAR·VN complex. The VN-binding epitope in uPAR seems to be the same in the 
presence of the different ligands, as mutation of the Trp32 and Arg91 is sufficient to 
abrogate both sc-uPA and complex induced binding to VN. However, further experiments 
are needed to clarify this issue. 
 
7.6.1 Future investigations 
 
Our data are preliminary and many aspects still need to be addressed. Some are briefly 
described below. 
PAI-1 has three potential N-glycosylation sites, with only two that are actually utilized 
(N209 and N265)207. The basic serpin inhibitory mechanism is not different between 
glycosylated and non-glycosylated PAI-1 (for instance, they display virtually identical 
second rate constant for the reaction with uPA). However, the presence of glycosylations 
has been shown to affect latency transition rate and binding to different monoclonal 
antibodies207. It has been suggested that glycans, at both positions, may establish several 
hydrogen bonds and hydrophobic interactions with the surrounding amino acids, thus 
changing the conformation of those regions of the protein. Since in our experiments, we 
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have employed recombinant PAI-1 expressed in E. coli and therefore lacking 
glycosylations, it will be important to confirm the super-agonist behaviour of the uPA·PAI-
1 complex using PAI-1 expressed in eukaryotic cells such as HEK293 cells.  
It is well-known that uPAR-bound uPA·PAI-1 complex is endocytosed by several 
members of the LDLR family, including LRP-1A, LRP-1B and VLDLR (reviewed in 49). 
In the HEK293 Flp-In cells, these proteins are not or poorly expressed, as determined by 
microarray analysis performed in our lab. One important point will be to assess whether 
these endocytic receptors are still capable to internalize the PAI-1·uPA·uPAR complex, 
when it is engaged with VN. On the other hand, it will be important to test the effect of 
uPA·PAI-1 treatment on cells with endogenous uPAR and LDLR. 
Other serpins have been shown to inhibit uPA in vitro. Testing the ability of such 
complexes (e.g. uPA·PAI-2 and uPA·PN-1) to induce uPAR binding to VN in binding 
experiments may clarify whether the super-agonist properties are peculiar of the uPA·PAI-
1 complex or a more general characteristic of the uPA·serpin complexes. This could also 




Historically, the uPA-system has been firstly linked with the promotion of pericellular 
proteolysis. The detection of uPA and uPAR at the invasive front of tumours74, 75 has 
further substantiated the notion that uPA is involved in cancer cell migration and 
dissemination. The specific uPA inhibitor, PAI-1, was therefore expected to be a marker of 
favourable outcome for cancer patients. On the contrary, PAI-1 clearly emerged as a potent 
prognostic marker of poor clinical outcome. Moreover, the combined assessment of uPA 
and PAI-1 was found to provide even superior prognostic information than either molecule 
alone208. This represents the so-called “uPA/PAI-1 paradox”.  
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A partial answer to this paradox has been given by the finding that the uPA-system exerts 
biological functions that are independent of the catalytic activity of uPA and mediated 
through the interaction with proteins in the pericellular space, such as VN, and the 
initiation of intracellular signalling.  In this context, uPA and PAI-1 may have different 
and non-opposing functions. 
The finding that the uPA·PAI-1 complex is a super-agonist of the uPAR/VN interaction 
provides a possible mechanistic explanation to the paradox. uPA and PAI-1 have opposite 
effects on uPAR-mediated adhesion to VN, when considered individually. The former is a 
well-established inducer of the uPAR/VN interaction122, 126, whereas the latter 
competitively inhibits the binding of uPAR to the SMB domain of VN102. In sharp 
contrast, the formation of the covalent complex between uPA and PAI-1 blocks these 
opposing effects and empowers the two molecules with potent agonistic properties. 
Since the uPAR/VN interaction has been shown to be necessary and sufficient to activate 
p130Cas and ERK pathways125, 137, the formation of the uPA·PAI-1 complex and the 
subsequent induction of the uPAR-binding to VN may be responsible for the triggering of 
migratory and mitogenic signals involved in tumour progression. 
Remarkably, the levels of the uPA·PAI-1 complex in tumour extracts have been shown to 
have independent prognostic as well as predictive values in breast cancer patients. 
Specifically, high levels of the complex correlate with poor prognosis in lymph node 
negative breast carcinomas209 and predict response to adjuvant systemic therapy in primary 
breast cancers210 as well as to endocrine therapy in advanced breast cancers211. Since, the 
formation of the complex requires active uPA and PAI-1, the authors suggest that the 
assessment of the complex levels may be a functional measurement of the active uPA and 
PAI-1 present in the tumour tissue and therefore provides more meaningful information 
compared to total PAI-1/uPA. We propose that the complex between uPA and PAI-1 is not 
only a measure of a past activity but is importantly endowed with peculiar characteristics 
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(i.e. super-agonist activity on the uPAR-mediated adhesion to VN) that directly contribute 
to the malignant phenotype. 
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